x
|
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
¨
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
Delaware
|
|
71-0872999
|
(State or other jurisdiction of
incorporation or organization)
|
|
(I.R.S. Employer
Identification No.)
|
|
|
|
200 Penobscot Drive, Redwood City
|
|
94063
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Large accelerated filer
|
¨
|
|
Accelerated filer
|
¨
|
|
|
|
|
|
Non-accelerated filer
|
¨
|
(Do not check if a smaller reporting company)
|
Smaller reporting company
|
x
|
|
PAGE
NUMBER
|
|
|
||
PART I. FINANCIAL INFORMATION
|
||
|
|
|
ITEM 1:
|
Financial Statements (Unaudited)
|
|
|
||
|
||
|
||
|
||
|
||
ITEM 2:
|
||
ITEM 3:
|
||
ITEM 4:
|
||
|
|
|
|
||
|
|
|
ITEM 1:
|
||
ITEM 1A:
|
||
ITEM 2:
|
||
ITEM 3:
|
||
ITEM 4:
|
||
ITEM 5:
|
||
ITEM 6:
|
||
|
|
September 30,
2015 |
|
December 31,
2014 |
||||
Assets
|
|
|
|
||||
Current assets:
|
|
|
|
||||
Cash and cash equivalents
|
$
|
16,963
|
|
|
$
|
26,487
|
|
Accounts receivable, net of allowances of $421 at September 30, 2015 and $428 at December 31, 2014
|
13,608
|
|
|
3,870
|
|
||
Inventories
|
678
|
|
|
1,395
|
|
||
Prepaid expenses and other current assets
|
1,092
|
|
|
1,255
|
|
||
Total current assets
|
32,341
|
|
|
33,007
|
|
||
Restricted cash
|
786
|
|
|
711
|
|
||
Marketable securities
|
1,231
|
|
|
688
|
|
||
Property and equipment, net
|
2,821
|
|
|
3,995
|
|
||
Intangible assets, net
|
3,655
|
|
|
6,186
|
|
||
Goodwill
|
3,241
|
|
|
3,241
|
|
||
Other non-current assets
|
265
|
|
|
294
|
|
||
Total assets
|
$
|
44,340
|
|
|
$
|
48,122
|
|
Liabilities and Stockholders' Equity
|
|
|
|
||||
Current liabilities:
|
|
|
|
||||
Accounts payable
|
$
|
1,174
|
|
|
$
|
4,673
|
|
Accrued compensation
|
2,554
|
|
|
2,946
|
|
||
Other accrued liabilities
|
2,151
|
|
|
2,619
|
|
||
Deferred revenue
|
6,949
|
|
|
3,497
|
|
||
Total current liabilities
|
12,828
|
|
|
13,735
|
|
||
Deferred revenue, net of current portion
|
4,316
|
|
|
3,813
|
|
||
Other long-term liabilities
|
3,888
|
|
|
4,263
|
|
||
Commitments and contingencies (Note 11)
|
|
|
|
|
|
||
Stockholders' equity:
|
|
|
|
||||
Preferred stock, $0.0001 par value; 5,000 shares authorized, none issued and outstanding
|
—
|
|
|
—
|
|
||
Common stock, $0.0001 par value; 100,000 shares authorized at September 30, 2015 and December 31, 2014; shares issued and outstanding of 40,300 at September 30, 2015 and 39,563 at December 31, 2014
|
4
|
|
|
4
|
|
||
Additional paid-in capital
|
304,561
|
|
|
302,379
|
|
||
Accumulated other comprehensive income (loss)
|
201
|
|
|
(142
|
)
|
||
Accumulated deficit
|
(281,458
|
)
|
|
(275,930
|
)
|
||
Total stockholders' equity
|
23,308
|
|
|
26,311
|
|
||
Total liabilities and stockholders' equity
|
$
|
44,340
|
|
|
$
|
48,122
|
|
|
Three Months Ended September 30,
|
|
Nine Months Ended September 30,
|
||||||||||||
|
2015
|
|
2014
|
|
2015
|
|
2014
|
||||||||
Revenues:
|
|
|
|
|
|
|
|
||||||||
Biocatalyst product sales
|
$
|
1,818
|
|
|
$
|
2,562
|
|
|
$
|
6,915
|
|
|
$
|
8,323
|
|
Biocatalyst research and development
|
14,517
|
|
|
3,364
|
|
|
19,247
|
|
|
7,176
|
|
||||
Revenue sharing arrangement
|
1,066
|
|
|
1,546
|
|
|
4,056
|
|
|
5,617
|
|
||||
Total revenues
|
17,401
|
|
|
7,472
|
|
|
30,218
|
|
|
21,116
|
|
||||
Costs and operating expenses:
|
|
|
|
|
|
|
|
||||||||
Cost of biocatalyst product sales
|
1,302
|
|
|
1,532
|
|
|
4,009
|
|
|
6,179
|
|
||||
Research and development
|
4,994
|
|
|
5,038
|
|
|
15,457
|
|
|
17,708
|
|
||||
Selling, general and administrative
|
5,415
|
|
|
5,157
|
|
|
16,289
|
|
|
16,791
|
|
||||
Total costs and operating expenses
|
11,711
|
|
|
11,727
|
|
|
35,755
|
|
|
40,678
|
|
||||
Income (loss) from operations
|
5,690
|
|
|
(4,255
|
)
|
|
(5,537
|
)
|
|
(19,562
|
)
|
||||
Interest income
|
4
|
|
|
3
|
|
|
12
|
|
|
15
|
|
||||
Other expenses
|
(26
|
)
|
|
(57
|
)
|
|
(147
|
)
|
|
(183
|
)
|
||||
Income (loss) before income taxes
|
5,668
|
|
|
(4,309
|
)
|
|
(5,672
|
)
|
|
(19,730
|
)
|
||||
Provision for (benefit from) income taxes
|
274
|
|
|
253
|
|
|
(144
|
)
|
|
(314
|
)
|
||||
Net income (loss)
|
$
|
5,394
|
|
|
$
|
(4,562
|
)
|
|
$
|
(5,528
|
)
|
|
$
|
(19,416
|
)
|
Net income (loss) per share, basic
|
$
|
0.14
|
|
|
$
|
(0.12
|
)
|
|
$
|
(0.14
|
)
|
|
$
|
(0.51
|
)
|
Net income (loss) per share, diluted
|
$
|
0.13
|
|
|
$
|
(0.12
|
)
|
|
$
|
(0.14
|
)
|
|
$
|
(0.51
|
)
|
Weighted average common shares used in computing net income (loss) per share, basic
|
39,767
|
|
|
38,450
|
|
|
39,340
|
|
|
38,063
|
|
||||
Weighted average common shares used in computing net income (loss) per share, diluted
|
40,970
|
|
|
38,450
|
|
|
39,340
|
|
|
38,063
|
|
|
Three Months Ended September 30,
|
|
Nine Months Ended September 30,
|
||||||||||||
|
2015
|
|
2014
|
|
2015
|
|
2014
|
||||||||
Net income (loss)
|
$
|
5,394
|
|
|
$
|
(4,562
|
)
|
|
$
|
(5,528
|
)
|
|
$
|
(19,416
|
)
|
Other comprehensive income (loss):
|
|
|
|
|
|
|
|
||||||||
Unrealized gain (loss) on marketable securities, net of tax expense of $263 and $160 for the three months ended September 30, 2015 and 2014, respectively, and tax benefit of $200 and $89 for the nine months ended September 30, 2015 and 2014, respectively.
|
(449
|
)
|
|
(261
|
)
|
|
343
|
|
|
145
|
|
||||
Other comprehensive income (loss)
|
(449
|
)
|
|
(261
|
)
|
|
343
|
|
|
145
|
|
||||
Total comprehensive income (loss)
|
$
|
4,945
|
|
|
$
|
(4,823
|
)
|
|
$
|
(5,185
|
)
|
|
$
|
(19,271
|
)
|
|
Nine Months Ended September 30,
|
||||||
|
2015
|
|
2014
|
||||
Operating activities:
|
|
|
|
||||
Net loss
|
$
|
(5,528
|
)
|
|
$
|
(19,416
|
)
|
Adjustments to reconcile net loss to net cash used in operating activities:
|
|
|
|
||||
Amortization of intangible assets
|
2,531
|
|
|
2,531
|
|
||
Depreciation and amortization of property and equipment
|
1,569
|
|
|
2,679
|
|
||
Impairment of property and equipment
|
—
|
|
|
1,841
|
|
||
Change in the fair value of assets held for sale
|
—
|
|
|
886
|
|
||
Gain on disposal of property and equipment
|
(5
|
)
|
|
(115
|
)
|
||
Income tax benefit related to marketable securities
|
(200
|
)
|
|
(89
|
)
|
||
Gain on sale of Hungarian subsidiary
|
—
|
|
|
(760
|
)
|
||
Stock-based compensation
|
3,759
|
|
|
3,630
|
|
||
Amortization of premium on marketable securities
|
—
|
|
|
2
|
|
||
Bad debt expense
|
—
|
|
|
53
|
|
||
Changes in operating assets and liabilities:
|
|
|
|
||||
Accounts receivable, net
|
(9,738
|
)
|
|
2,316
|
|
||
Inventories, net
|
717
|
|
|
(456
|
)
|
||
Prepaid expenses and other current assets
|
163
|
|
|
(734
|
)
|
||
Other assets
|
29
|
|
|
15
|
|
||
Accounts payable
|
(3,499
|
)
|
|
(1,418
|
)
|
||
Accrued compensation
|
(393
|
)
|
|
(1,100
|
)
|
||
Other accrued liabilities
|
(842
|
)
|
|
194
|
|
||
Deferred revenue
|
3,955
|
|
|
5,288
|
|
||
Net cash used in operating activities
|
(7,482
|
)
|
|
(4,653
|
)
|
||
Investing activities:
|
|
|
|
||||
Purchase of property and equipment
|
(395
|
)
|
|
(267
|
)
|
||
Proceeds from maturities of marketable securities
|
—
|
|
|
3,000
|
|
||
Proceeds from sale of Hungarian subsidiary, net of selling costs
|
—
|
|
|
1,500
|
|
||
Proceeds from the sale of assets held for sale
|
—
|
|
|
281
|
|
||
Proceeds from sale of property and equipment
|
5
|
|
|
166
|
|
||
Increase in restricted cash
|
(75
|
)
|
|
—
|
|
||
Net cash provided by (used in) investing activities
|
(465
|
)
|
|
4,680
|
|
||
Financing activities:
|
|
|
|
||||
Proceeds from exercises of options to purchase common stock
|
235
|
|
|
180
|
|
||
Taxes paid related to net share settlement of equity awards
|
(1,812
|
)
|
|
(815
|
)
|
||
Net cash used in financing activities
|
(1,577
|
)
|
|
(635
|
)
|
||
Net decrease in cash and cash equivalents
|
(9,524
|
)
|
|
(608
|
)
|
||
Cash and cash equivalents at the beginning of the period
|
26,487
|
|
|
22,130
|
|
||
Cash and cash equivalents at the end of the period
|
$
|
16,963
|
|
|
$
|
21,522
|
|
•
|
Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities.
|
•
|
Level 2: Directly or indirectly observable inputs as of the reporting date through correlation with market data, including quoted prices for similar assets and liabilities in active markets and quoted prices in markets that are not active. Level 2 also includes assets and liabilities that are valued using models or other pricing methodologies that do not require significant judgment since the input assumptions used in the models, such as interest rates and volatility factors, are corroborated by readily observable data from actively quoted markets for substantially the full term of the financial instrument.
|
•
|
Level 3: Unobservable inputs that are supported by little or no market activity and reflect the use of significant management judgment. These values are generally determined using pricing models for which the assumptions utilize management's estimates of market participant assumptions.
|
|
Three Months Ended September 30,
|
|
Nine Months Ended September 30,
|
||||||||||||
|
2015
|
|
2014
|
|
2015
|
|
2014
|
||||||||
Numerator
|
|
|
|
|
|
|
|
||||||||
Net income (loss)
|
$
|
5,394
|
|
|
$
|
(4,562
|
)
|
|
$
|
(5,528
|
)
|
|
$
|
(19,416
|
)
|
Denominator
|
|
|
|
|
|
|
|
||||||||
Weighted average common shares used in computing net income (loss) per share, basic
|
39,767
|
|
|
38,450
|
|
|
39,340
|
|
|
38,063
|
|
||||
Effect of dilutive shares
|
1,203
|
|
|
—
|
|
|
—
|
|
|
—
|
|
||||
Weighted average common shares used in computing net income (loss) per share, diluted
|
40,970
|
|
|
38,450
|
|
|
39,340
|
|
|
38,063
|
|
||||
Net income (loss) per share, basic
|
$
|
0.14
|
|
|
$
|
(0.12
|
)
|
|
$
|
(0.14
|
)
|
|
$
|
(0.51
|
)
|
Net income (loss) per share, diluted
|
$
|
0.13
|
|
|
$
|
(0.12
|
)
|
|
$
|
(0.14
|
)
|
|
$
|
(0.51
|
)
|
|
Three Months Ended September 30,
|
|
Nine Months Ended September 30,
|
||||||||
|
2015
|
|
2014
|
|
2015
|
|
2014
|
||||
Shares issuable under Equity Incentive Plan
|
—
|
|
|
6,398
|
|
|
6,121
|
|
|
6,398
|
|
Shares issuable upon the conversion of warrants
|
—
|
|
|
75
|
|
|
75
|
|
|
75
|
|
Total shares excluded as anti-dilutive
|
—
|
|
|
6,473
|
|
|
6,196
|
|
|
6,473
|
|
|
September 30, 2015
|
||||||||||||||||
|
Adjusted Cost
|
|
Gross
Unrealized Gains |
|
Gross
Unrealized Losses |
|
Estimated
Fair Value |
|
Average
Contractual Maturities |
||||||||
|
|
|
(in days)
|
||||||||||||||
Money market funds (1)
|
$
|
11,115
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
11,115
|
|
|
n/a
|
Common shares of CO
2
Solutions (2)
|
563
|
|
|
668
|
|
|
—
|
|
|
1,231
|
|
|
n/a
|
||||
Total
|
$
|
11,678
|
|
|
$
|
668
|
|
|
$
|
—
|
|
|
$
|
12,346
|
|
|
|
|
December 31, 2014
|
||||||||||||||||
|
Adjusted Cost
|
|
Gross
Unrealized Gains |
|
Gross
Unrealized Losses |
|
Estimated
Fair Value |
|
Average
Contractual Maturities |
||||||||
|
|
|
(in days)
|
||||||||||||||
Money market funds (1)
|
$
|
14,602
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
14,602
|
|
|
n/a
|
Common shares of CO
2
Solutions (2)
|
563
|
|
|
125
|
|
|
—
|
|
|
688
|
|
|
n/a
|
||||
Total
|
$
|
15,165
|
|
|
$
|
125
|
|
|
$
|
—
|
|
|
$
|
15,290
|
|
|
|
|
September 30, 2015
|
||||||||||||||
|
Level 1
|
|
Level 2
|
|
Level 3
|
|
Total
|
||||||||
Money market funds
|
$
|
11,115
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
11,115
|
|
Common shares of CO
2
Solutions
|
—
|
|
|
1,231
|
|
|
—
|
|
|
1,231
|
|
||||
Total
|
$
|
11,115
|
|
|
$
|
1,231
|
|
|
$
|
—
|
|
|
$
|
12,346
|
|
|
December 31, 2014
|
||||||||||||||
|
Level 1
|
|
Level 2
|
|
Level 3
|
|
Total
|
||||||||
Money market funds
|
$
|
14,602
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
14,602
|
|
Common shares of CO
2
Solutions
|
—
|
|
|
688
|
|
|
—
|
|
|
688
|
|
||||
Total
|
$
|
14,602
|
|
|
$
|
688
|
|
|
$
|
—
|
|
|
$
|
15,290
|
|
|
September 30, 2015
|
|
December 31, 2014
|
||||
Raw materials
|
$
|
182
|
|
|
$
|
84
|
|
Work-in-process
|
11
|
|
|
65
|
|
||
Finished goods
|
485
|
|
|
1,246
|
|
||
Inventories
|
$
|
678
|
|
|
$
|
1,395
|
|
|
September 30, 2015
|
|
December 31, 2014
|
||||
Laboratory equipment
|
$
|
21,354
|
|
|
$
|
23,002
|
|
Leasehold improvements
|
9,782
|
|
|
9,773
|
|
||
Computer equipment
|
3,271
|
|
|
3,262
|
|
||
Office furniture and equipment
|
1,227
|
|
|
1,227
|
|
||
Construction in progress (1)
|
151
|
|
|
24
|
|
||
Property and equipment
|
35,785
|
|
|
37,288
|
|
||
Less: accumulated depreciation and amortization
|
(32,964
|
)
|
|
(31,452
|
)
|
||
Less: impairment of laboratory equipment (2)
|
—
|
|
|
(1,841
|
)
|
||
Property and equipment, net
|
$
|
2,821
|
|
|
$
|
3,995
|
|
|
September 30, 2015
|
|
December 31, 2014
|
|
|
||||||||||||||||||||
|
Gross
Carrying
Amount
|
|
Accumulated
Amortization
|
|
Net
Carrying
Amount
|
|
Gross
Carrying
Amount
|
|
Accumulated
Amortization
|
|
Net
Carrying
Amount
|
|
Amortization
Period
|
||||||||||||
|
|
|
|
|
|
|
|
|
(years)
|
||||||||||||||||
Maxygen intellectual property
|
$
|
20,244
|
|
|
$
|
(16,589
|
)
|
|
$
|
3,655
|
|
|
$
|
20,244
|
|
|
$
|
(14,058
|
)
|
|
$
|
6,186
|
|
|
6
|
Year ending December 31:
|
Total
|
||
2015 (remaining 3 months)
|
$
|
843
|
|
2016
|
2,812
|
|
|
|
$
|
3,655
|
|
|
Three Months Ended September 30,
|
|
Nine Months Ended September 30,
|
||||||||||||
|
2015
|
|
2014
|
|
2015
|
|
2014
|
||||||||
Research and development (1)
|
$
|
181
|
|
|
$
|
227
|
|
|
$
|
710
|
|
|
$
|
734
|
|
Selling, general and administrative
|
1,042
|
|
|
828
|
|
|
3,049
|
|
|
2,896
|
|
||||
Total
|
$
|
1,223
|
|
|
$
|
1,055
|
|
|
$
|
3,759
|
|
|
$
|
3,630
|
|
|
Three Months Ended September 30,
|
|
Nine Months Ended September 30,
|
||||||||||||
|
2015
|
|
2014
|
|
2015
|
|
2014
|
||||||||
Stock options
|
$
|
281
|
|
|
$
|
247
|
|
|
$
|
798
|
|
|
$
|
843
|
|
RSUs and RSAs
|
566
|
|
|
722
|
|
|
2,020
|
|
|
2,383
|
|
||||
PSUs
|
376
|
|
|
86
|
|
|
941
|
|
|
404
|
|
||||
Total
|
$
|
1,223
|
|
|
$
|
1,055
|
|
|
$
|
3,759
|
|
|
$
|
3,630
|
|
|
Three Months Ended September 30,
|
|
Nine Months Ended September 30,
|
||||||||||||
|
2015
|
|
2014
|
|
2015
|
|
2014
|
||||||||
Expected term (in years) (1)
|
5.2
|
|
|
6.0
|
|
|
6.0
|
|
|
6.0
|
|
||||
Volatility
|
67
|
%
|
|
68
|
%
|
|
66
|
%
|
|
65
|
%
|
||||
Risk-free interest rate
|
1.64
|
%
|
|
1.91
|
%
|
|
1.70
|
%
|
|
1.915
|
%
|
||||
Dividend yield
|
—
|
%
|
|
—
|
%
|
|
—
|
%
|
|
—
|
%
|
||||
Weighted-average estimated fair value of stock options granted
|
$
|
2.31
|
|
|
$
|
1.43
|
|
|
$
|
2.09
|
|
|
$
|
1.20
|
|
September 30, 2015
|
|||||||
Issue Date
|
Shares Subject
to Warrants
|
|
Exercise Price
per Share
|
|
Expiration
|
||
July 17, 2007
|
2,384
|
|
$
|
12.45
|
|
|
February 9, 2016
|
September 28, 2007
|
72,727
|
|
$
|
8.25
|
|
|
September 28, 2017
|
|
Lease payments
|
||
Years ending December 31,
|
|
||
2015 (3 months remaining)
|
$
|
689
|
|
2016
|
2,827
|
|
|
2017
|
2,677
|
|
|
2018
|
2,736
|
|
|
2019 and beyond
|
3,054
|
|
|
Total
|
$
|
11,983
|
|
|
Percentage of Total Revenues for the
|
||||||||||
|
Three Months Ended September 30,
|
|
Nine Months Ended September 30,
|
||||||||
|
2015
|
|
2014
|
|
2015
|
|
2014
|
||||
Customer A
|
39
|
%
|
|
27
|
%
|
|
34
|
%
|
|
26
|
%
|
Customer B
|
40
|
%
|
|
*
|
|
|
26
|
%
|
|
*
|
|
Customer C (related party)
|
*
|
|
|
21
|
%
|
|
13
|
%
|
|
27
|
%
|
|
Percentage of Accounts Receivables at
|
||||
|
September 30, 2015
|
|
December 31, 2014
|
||
Customer A
|
42
|
%
|
|
63
|
%
|
Customer B
|
47
|
%
|
|
2
|
%
|
Customer C (related party)
|
*
|
|
|
—
|
%
|
|
Three Months Ended September 30,
|
|
Nine Months Ended September 30,
|
||||||||||||
|
2015
|
|
2014
|
|
2015
|
|
2014
|
||||||||
Revenues:
|
|
|
|
|
|
|
|
||||||||
United States
|
$
|
8,755
|
|
|
$
|
4,747
|
|
|
$
|
16,516
|
|
|
$
|
12,518
|
|
Asia
|
|
|
|
|
|
|
|
||||||||
India
|
369
|
|
|
225
|
|
|
519
|
|
|
636
|
|
||||
Others
|
619
|
|
|
658
|
|
|
1,305
|
|
|
1,338
|
|
||||
Europe
|
|
|
|
|
|
|
|
||||||||
Ireland
|
160
|
|
|
—
|
|
|
160
|
|
|
2,744
|
|
||||
Others
|
7,498
|
|
|
1,842
|
|
|
11,712
|
|
|
3,864
|
|
||||
Other
|
—
|
|
|
—
|
|
|
6
|
|
|
16
|
|
||||
Total revenues
|
$
|
17,401
|
|
|
$
|
7,472
|
|
|
$
|
30,218
|
|
|
$
|
21,116
|
|
|
September 30, 2015
|
|
December 31, 2014
|
||||
Long-lived assets
|
|
|
|
||||
United States
|
$
|
6,741
|
|
|
$
|
10,475
|
|
ITEM 2.
|
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
|
|
Three months ended September 30,
|
|
Change
|
|
Nine months ended September 30,
|
|
Change
|
||||||||||||||||||||||
|
2015
|
|
2014
|
|
$
|
|
%
|
|
2015
|
|
2014
|
|
$
|
|
%
|
||||||||||||||
Revenues:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||
Biocatalyst product sales
|
$
|
1,818
|
|
|
$
|
2,562
|
|
|
$
|
(744
|
)
|
|
(29
|
)%
|
|
$
|
6,915
|
|
|
$
|
8,323
|
|
|
$
|
(1,408
|
)
|
|
(17
|
)%
|
Biocatalyst research and development
|
14,517
|
|
|
3,364
|
|
|
11,153
|
|
|
332
|
%
|
|
19,247
|
|
|
7,176
|
|
|
12,071
|
|
|
168
|
%
|
||||||
Revenue sharing arrangement
|
1,066
|
|
|
1,546
|
|
|
(480
|
)
|
|
(31
|
)%
|
|
4,056
|
|
|
5,617
|
|
|
(1,561
|
)
|
|
(28
|
)%
|
||||||
Total revenues
|
17,401
|
|
|
7,472
|
|
|
9,929
|
|
|
133
|
%
|
|
30,218
|
|
|
21,116
|
|
|
9,102
|
|
|
43
|
%
|
||||||
Costs and operating expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||
Cost of biocatalyst product sales
|
1,302
|
|
|
1,532
|
|
|
(230
|
)
|
|
(15
|
)%
|
|
4,009
|
|
|
6,179
|
|
|
(2,170
|
)
|
|
(35
|
)%
|
||||||
Research and development
|
4,994
|
|
|
5,038
|
|
|
(44
|
)
|
|
(1
|
)%
|
|
15,457
|
|
|
17,708
|
|
|
(2,251
|
)
|
|
(13
|
)%
|
||||||
Selling, general and administrative
|
5,415
|
|
|
5,157
|
|
|
258
|
|
|
5
|
%
|
|
16,289
|
|
|
16,791
|
|
|
(502
|
)
|
|
(3
|
)%
|
||||||
Total costs and operating expenses
|
11,711
|
|
|
11,727
|
|
|
(16
|
)
|
|
—
|
%
|
|
35,755
|
|
|
40,678
|
|
|
(4,923
|
)
|
|
(12
|
)%
|
||||||
Income (loss) from operations
|
5,690
|
|
|
(4,255
|
)
|
|
9,945
|
|
|
(234
|
)%
|
|
(5,537
|
)
|
|
(19,562
|
)
|
|
14,025
|
|
|
(72
|
)%
|
||||||
Interest income
|
4
|
|
|
3
|
|
|
1
|
|
|
33
|
%
|
|
12
|
|
|
15
|
|
|
(3
|
)
|
|
(20
|
)%
|
||||||
Other expenses
|
(26
|
)
|
|
(57
|
)
|
|
31
|
|
|
(54
|
)%
|
|
(147
|
)
|
|
(183
|
)
|
|
36
|
|
|
(20
|
)%
|
||||||
Income (loss) before income taxes
|
5,668
|
|
|
(4,309
|
)
|
|
9,977
|
|
|
(232
|
)%
|
|
(5,672
|
)
|
|
(19,730
|
)
|
|
14,058
|
|
|
(71
|
)%
|
||||||
Provision for (benefit from) income taxes
|
274
|
|
|
253
|
|
|
21
|
|
|
8
|
%
|
|
(144
|
)
|
|
(314
|
)
|
|
170
|
|
|
(54
|
)%
|
||||||
Net income (loss)
|
$
|
5,394
|
|
|
$
|
(4,562
|
)
|
|
$
|
9,956
|
|
|
(218
|
)%
|
|
$
|
(5,528
|
)
|
|
$
|
(19,416
|
)
|
|
$
|
13,888
|
|
|
(72
|
)%
|
|
Three months ended September 30,
|
|
Change
|
|
Nine months ended September 30,
|
|
Change
|
||||||||||||||||||||||
(In Thousands)
|
2015
|
|
2014
|
|
$
|
|
%
|
|
2015
|
|
2014
|
|
$
|
|
%
|
||||||||||||||
Biocatalyst product sales
|
$
|
1,818
|
|
|
$
|
2,562
|
|
|
$
|
(744
|
)
|
|
(29
|
)%
|
|
$
|
6,915
|
|
|
$
|
8,323
|
|
|
$
|
(1,408
|
)
|
|
(17
|
)%
|
Biocatalyst research and development
|
14,517
|
|
|
3,364
|
|
|
11,153
|
|
|
332
|
%
|
|
19,247
|
|
|
7,176
|
|
|
12,071
|
|
|
168
|
%
|
||||||
Revenue sharing arrangement
|
1,066
|
|
|
1,546
|
|
|
(480
|
)
|
|
(31
|
)%
|
|
4,056
|
|
|
5,617
|
|
|
(1,561
|
)
|
|
(28
|
)%
|
||||||
Total revenues
|
$
|
17,401
|
|
|
$
|
7,472
|
|
|
$
|
9,929
|
|
|
133
|
%
|
|
$
|
30,218
|
|
|
$
|
21,116
|
|
|
$
|
9,102
|
|
|
43
|
%
|
|
Three months ended September 30,
|
|
Change
|
|
Nine months ended September 30,
|
|
Change
|
||||||||||||||||||||||
(In Thousands)
|
2015
|
|
2014
|
|
$
|
|
%
|
|
2015
|
|
2014
|
|
$
|
|
%
|
||||||||||||||
Cost of biocatalyst product sales
|
$
|
1,302
|
|
|
$
|
1,532
|
|
|
$
|
(230
|
)
|
|
(15
|
)%
|
|
$
|
4,009
|
|
|
$
|
6,179
|
|
|
$
|
(2,170
|
)
|
|
(35
|
)%
|
Research and development
|
4,994
|
|
|
5,038
|
|
|
(44
|
)
|
|
(1
|
)%
|
|
15,457
|
|
|
17,708
|
|
|
(2,251
|
)
|
|
(13
|
)%
|
||||||
Selling, general and administrative
|
5,415
|
|
|
5,157
|
|
|
258
|
|
|
5
|
%
|
|
16,289
|
|
|
16,791
|
|
|
(502
|
)
|
|
(3
|
)%
|
||||||
Total operating expenses
|
$
|
11,711
|
|
|
$
|
11,727
|
|
|
$
|
(16
|
)
|
|
—
|
%
|
|
$
|
35,755
|
|
|
$
|
40,678
|
|
|
$
|
(4,923
|
)
|
|
(12
|
)%
|
|
Three months ended September 30,
|
|
Change
|
|
Nine months ended September 30,
|
|
Change
|
||||||||||||||||||||||
(In Thousands)
|
2015
|
|
2014
|
|
$
|
|
%
|
|
2015
|
|
2014
|
|
$
|
|
%
|
||||||||||||||
Biocatalyst product sales
|
$
|
1,818
|
|
|
|
$2,562
|
|
|
$
|
(744
|
)
|
|
(29
|
)%
|
|
$
|
6,915
|
|
|
$
|
8,323
|
|
|
$
|
(1,408
|
)
|
|
(17
|
)%
|
Cost of biocatalyst product sales
|
1,302
|
|
|
1,532
|
|
|
(230
|
)
|
|
(15
|
)%
|
|
4,009
|
|
|
6,179
|
|
|
(2,170
|
)
|
|
(35
|
)%
|
||||||
Biocatalyst product gross profit
|
$
|
516
|
|
|
|
$1,030
|
|
|
$
|
(514
|
)
|
|
(50
|
)%
|
|
$
|
2,906
|
|
|
$
|
2,144
|
|
|
$
|
762
|
|
|
36
|
%
|
Product gross margin (%)
|
28%
|
|
40%
|
|
|
|
|
|
42%
|
|
26%
|
|
|
|
|
|
|
|
Three months ended September 30,
|
|
Change
|
|
Nine months ended September 30,
|
|
Change
|
||||||||||||||||||||||
(In Thousands)
|
2015
|
|
2014
|
|
$
|
|
%
|
|
2015
|
|
2014
|
|
$
|
|
%
|
||||||||||||||
Interest income
|
$
|
4
|
|
|
$
|
3
|
|
|
$
|
1
|
|
|
33
|
%
|
|
$
|
12
|
|
|
$
|
15
|
|
|
$
|
(3
|
)
|
|
(20
|
)%
|
Other expenses
|
(26
|
)
|
|
(57
|
)
|
|
31
|
|
|
(54
|
)%
|
|
(147
|
)
|
|
(183
|
)
|
|
36
|
|
|
(20
|
)%
|
||||||
Total other expenses
|
$
|
(22
|
)
|
|
$
|
(54
|
)
|
|
$
|
32
|
|
|
(59
|
)%
|
|
$
|
(135
|
)
|
|
$
|
(168
|
)
|
|
$
|
33
|
|
|
(20
|
)%
|
(In Thousands)
|
September 30, 2015
|
|
December 31, 2014
|
||||
Cash and cash equivalents
|
$
|
16,963
|
|
|
$
|
26,487
|
|
Working capital
|
$
|
19,513
|
|
|
$
|
19,272
|
|
|
Nine months ended September 30,
|
||||||
(In Thousands)
|
2015
|
|
2014
|
||||
Net cash used in operating activities
|
$
|
(7,482
|
)
|
|
$
|
(4,653
|
)
|
Net cash provided by (used in) investing activities
|
(465
|
)
|
|
4,680
|
|
||
Net cash used in financing activities
|
(1,577
|
)
|
|
(635
|
)
|
||
Net decrease in cash and cash equivalents
|
$
|
(9,524
|
)
|
|
$
|
(608
|
)
|
ITEM 3.
|
QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
|
ITEM 4.
|
CONTROLS AND PROCEDURES
|
ITEM 1.
|
LEGAL PROCEEDINGS
|
ITEM 1A.
|
RISK FACTORS
|
ITEM 2.
|
UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
|
ITEM 3.
|
DEFAULTS UPON SENIOR SECURITIES
|
ITEM 4.
|
MINE SAFETY DISCLOSURES
|
ITEM 5.
|
OTHER INFORMATION
|
ITEM 6.
|
EXHIBITS
|
|
|
|
|
|
|
Codexis, Inc.
|
|
|
|
|
|
Date:
|
November 5, 2015
|
By:
|
/s/ John Nicols
|
|
|
|
John Nicols
President and Chief Executive Officer
(principal executive officer)
|
|
|
|
|
Date:
|
November 5, 2015
|
By:
|
/s/ Gordon Sangster
|
|
|
|
Gordon Sangster
Chief Financial Officer
(principal financial and accounting officer)
|
ITEM 6.
|
Exhibits
|
3.1
|
|
|
Amended and Restated Certificate of Incorporation of Codexis, Inc. filed with the Secretary of the State of the State of Delaware on April 27, 2010 and effective as of April 27, 2010 (incorporated by reference to Exhibit 3.1 to the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2010, filed on May 28, 2010).
|
|
|
|
|
3.2
|
|
|
Certificate of Designations of Series A Junior Participating Preferred Stock of Codexis, Inc., filed with the Secretary of State of the State of Delaware on September 4, 2012 (incorporated by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K, filed on September 4, 2012).
|
|
|
|
|
3.3
|
|
|
Amended and Restated Bylaws of Codexis, Inc. effective as of April 27, 2010 (incorporated by reference to Exhibit 3.2 to the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2010, filed on May 28, 2010).
|
|
|
|
|
4.1
|
|
|
Form of the Company's Common Stock Certificate (incorporated by reference to Exhibit 4.1 to the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2012, filed on August 9, 2012).
|
|
|
|
|
10.1†
|
|
|
Platform Technology Transfer and License Agreement by and between the Company and Merck Sharp & Dohme Corp., dated as of August 3, 2015.
|
|
|
|
|
31.1
|
|
|
Certification of Principal Executive Officer Required Under Rule 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as amended.
|
|
|
|
|
31.2
|
|
|
Certification of Principal Financial Officer Required Under Rule 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as amended.
|
|
|
|
|
32.1
|
|
|
Certification of Principal Executive Officer and Principal Financial Officer Required Under Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, and 18 U.S.C. §1350.
|
|
|
|
|
101
|
|
|
The following materials from the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2015, formatted in Extensible Business Reporting Language (XBRL) includes: (i) Condensed Consolidated Balance Sheets at September 30, 2015 and December 31, 2014, (ii) Condensed Consolidated Statements of Income for the Three and Nine Months Ended September 30, 2015 and 2014, (iii) Condensed Consolidated Statements of Comprehensive Income (Loss) for the Three and Nine Months Ended September 30, 2015 and 2014, (iv) Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2015 and 2014, and (v) Notes to Condensed Consolidated Financial Statements.
|
CONFIDENTIAL
[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
|
Technology Transfer Milestone Event
|
Milestone Payment
|
Completion of Wave 1
|
$5,000,000.00
|
Completion of Wave 2
|
$8,000,000.00
|
[***] Merck Developed API manufactured using at least one (1) Enzyme
|
[***] Payment
|
[***]
|
$[***]
|
[***]
|
$[***]
|
Termination at Will
|
Termination At Will Payment
|
At any time after Wave 1, as defined in the Technology Transfer Plan
|
$8,000,000.00
|
if to Merck, to:
|
Merck Sharp & Dohme Corp.
|
|
One Merck Drive
|
|
P.O. Box 100, WS3A-65
|
|
Whitehouse Station, NJ 08889-0100
|
|
Attention: [***]
|
|
Facsimile No.: [***]
|
|
|
and
|
Merck Sharp & Dohme Corp.
|
|
2000 Galloping Hill Road
|
|
Kenilworth, NJ 07033
|
|
Attention: [***]
|
|
Facsimile: [***]
|
Codexis, Inc.
|
Merck Sharp & Dohme Corp.
|
By: /s/ John Nicols
|
By: /s/ Iain Dukes
|
Name: John Nicols
|
Name: Iain Dukes, D. Phil
|
Title: President and CEO
|
Title: Senior Vice President
|
CODEXIS CORE PATENTS
|
|||||||
Country
|
Application Title
|
Application Status
|
Application Number
|
Filing Date
|
Publication Number
|
Patent Number
|
Issue Date
|
US
|
COMBINED AUTOMATED PARALLEL SYNTHESIS OF POLYNUCLEOTIDE VARIANTS
|
Granted
|
12/562,988
|
09/18/2009
|
US-2010-0093560A1
|
8383346
|
02/26/2013
|
CN
|
METHOD OF SYNTHESIZING POLYNUCLEOTIDE VARIANTS
|
Granted
|
200980122093.2
|
12/13/2010
|
102066561
|
200980122093.2
|
09/25/2013
|
CA
|
METHOD OF SYNTHESIZING POLYNUCLEOTIDE VARIANTS
|
Granted
|
2,726,850
|
12/02/2010
|
2726850
|
2726850
|
06/02/2015
|
EP
|
METHOD OF SYNTHESIZING POLYNUCLEOTIDE VARIANTS
|
Allowed
|
9763625.2
|
11/29/2010
|
2285958
|
|
|
IN
|
METHOD OF SYNTHESIZING POLYNUCLEOTIDE VARIANTS
|
Published
|
8090/CHEN/2010
|
12/13/2010
|
8090/CHENP/2010A
|
|
|
SG
|
METHOD OF SYNTHESIZING POLYNUCLEOTIDE VARIANTS
|
Granted
|
201009215-3
|
12/13/2010
|
|
167342
|
05/31/2013
|
CA
|
COMBINED AUTOMATED PARALLEL SYNTHESIS OF POLYNUCLEOTIDE VARIANTS
|
Allowed
|
2763017
|
11/21/2011
|
2763017
|
|
|
CN
|
COMBINED AUTOMATED PARALLEL SYNTHESIS OF POLYNUCLEOTIDE VARIANTS
|
Granted
|
200980159766.1
|
12/08/2011
|
102803489
|
ZL200980159766.1
|
01/28/2015
|
EP
|
COMBINED AUTOMATED PARALLEL SYNTHESIS OF POLYNUCLEOTIDE VARIANTS
|
Published
|
9845944.9
|
12/05/2011
|
2451951
|
|
|
IN
|
COMBINED AUTOMATED PARALLEL SYNTHESIS OF POLYNUCLEOTIDE VARIANTS
|
Published
|
9101/CHENP/2011
|
12/07/2011
|
9101/CHENP/2011 A
|
|
|
US
|
COMBINED AUTOMATED PARALLEL SYNTHESIS OF POLYNUCLEOTIDE VARIANTS
|
Published
|
14/505209
|
10/02/2014
|
20150024971
|
|
|
US
|
METHOD OF SELECTING AN OPTIMIZED, DIVERSE POPULATION OF VARIANTS
|
Granted
|
12/867429
|
08/12/2010
|
US20110029468
|
8504498
|
08/06/2013
|
CODEXIS CORE PATENTS
|
|||||||
EP
|
METHOD OF SELECTING AN OPTIMIZED, DIVERSE POPULATION OF VARIANTS
|
Published
|
9710859.1
|
02/12/2009
|
2250595
|
|
|
EP
|
METHOD OF GENERATING AN OPTIMIZED, DIVERSE POPULATION OF VARIANTS
|
Published
|
9710490.5
|
02/12/2009
|
2250594
|
|
|
US
|
METHOD OF GENERATING AN OPTIMIZED, DIVERSE POPULATION OF VARIANTS
|
Granted
|
12/867433
|
10/21/2010
|
2011-0034342
|
8768871
|
07/01/2014
|
US
|
METHOD OF GENERATING AN OPTIMIZED, DIVERSE POPULATION OF VARIANTS
|
Published
|
14/281421
|
05/19/2014
|
2014/0256557
|
|
|
EP
|
REDUCED CODON MUTAGENESIS
|
Published
|
10817881.5
|
03/30/2012
|
2478137
|
|
|
US
|
PROTEIN VARIANT GENERATION BY REGION SHUFFLING
|
Published
|
13/577,651
|
08/07/2012
|
2014/0005057
|
|
|
EP
|
PROTEIN VARIANT GENERATION BY REGION SHUFFLING
|
Published
|
12803889.0
|
12/12/2013
|
2726651
|
|
|
US
|
GENE SHUFFLING METHODS
|
Published
|
14/385060
|
09/12/2014
|
20150050658
|
|
|
EP
|
GENE SHUFFLING METHODS
|
Published
|
13760490.6
|
10/14/2014
|
2825647
|
|
|
US
|
METHODS, SYSTEMS, AND SOFTWARE FOR IDENTIFYING BIO-MOLECULES WITH INTERACTING COMPONENTS
|
Published
|
14/167709
|
01/29/2014
|
20140214391
|
|
|
WO
|
METHODS, SYSTEMS, AND SOFTWARE FOR IDENTIFYING BIO-MOLECULES WITH INTERACTING COMPONENTS
|
Published
|
PCT/US2014/013666
|
01/29/2014
|
WO2014120819
|
|
|
US
|
STRUCTURE BASED PREDICTIVE MODELING
|
Published
|
14/498881
|
09/26/2014
|
20150134315
|
|
|
WO
|
STRUCTURE BASED PREDICTIVE MODELING
|
Published
|
PCT/US2014/057900
|
09/26/2014
|
WO2015048573
|
|
|
US
|
AUTOMATED SCREENING OF ENZYME VARIANTS
|
Published
|
14/498864
|
09/26/2014
|
20150133307
|
|
|
CODEXIS CORE PATENTS
|
|||||||
WO
|
AUTOMATED SCREENING OF ENZYME VARIANTS
|
Published
|
PCT/US2014/057899
|
09/26/2014
|
WO2015048572
|
|
|
US
|
METHODS, SYSTEMS, AND SOFTWARE FOR IDENTIFYING BIO-MOLECULES USING MODELS OF MULTIPLICATIVE FORM
|
Published
|
14/167713
|
01/29/2014
|
20140221216
|
|
|
WO
|
METHODS, SYSTEMS, AND SOFTWARE FOR IDENTIFYING BIO-MOLECULES USING MODELS OF MULTIPLICATIVE FORM
|
Published
|
PCT/US2014/013668
|
01/29/2014
|
WO2014120821
|
|
|
CODEXIS ENZYME PATENTS
|
|||||||
Country
|
Application Title
|
Application Status
|
Application Number
|
Filing Date
|
Publication Number
|
Patent Number
|
Issue Date
|
US
|
TRANSAMINASE POLYPEPTIDES
|
Granted
|
12/684,864
|
01/08/2010
|
20100209981A1
|
8470564
|
06/25/2013
|
EP
|
TRANSAMINASE POLYPEPTIDES
|
Published
|
10729606.3
|
01/08/2010
|
2385983
|
|
|
SG
|
TRANSAMINASE POLYPEPTIDES
|
Granted
|
201104947-5
|
07/06/2011
|
172891
|
172891
|
11/26/2014
|
IN
|
TRANSAMINASE POLYPEPTIDES
|
Published
|
5648/CHENP/2011
|
08/04/2011
|
5648/CHENP/2011
|
|
|
IL
|
TRANSAMINASE POLYPEPTIDES
|
Pending
|
213950
|
07/06/2011
|
|
|
|
CN
|
TRANSAMINASE POLYPEPTIDES
|
Granted
|
201080010926.9
|
01/08/2010
|
102341494
|
ZL201080010926.9
|
10/15/2014
|
US
|
TRANSAMINASE POLYPEPTIDES
|
Granted
|
13/920,902
|
06/18/2013
|
2013/0266994A1
|
9029106
|
05/12/2015
|
US
|
TRANSAMINASE POLYPEPTIDES
|
Pending
|
14/684916
|
04/13/2015
|
|
|
|
US
|
TRANSAMINASE BIOCATALYSTS
|
Granted
|
12/714,397
|
02/26/2010
|
20100285541A1
|
8293507
|
10/23/2012
|
CN
|
TRANSAMINASE BIOCATALYSTS
|
Granted
|
201080017312.3
|
10/19/2011
|
102405281
|
102405281
|
05/13/2015
|
EP
|
TRANSAMINASE BIOCATALYSTS
|
Granted
|
10746948.8
|
09/26/2011
|
2401366
|
2401366
|
12/18/2013
|
IN
|
TRANSAMINASE BIOCATALYSTS
|
Published
|
6857/CHENP/2011
|
09/22/2011
|
6857/CHENP/2011
|
|
|
SG
|
TRANSAMINASE BIOCATALYSTS
|
Granted
|
201106064-7
|
02/26/2010
|
173815
|
173815
|
11/15/2013
|
JP
|
TRANSAMINASE BIOCATALYSTS
|
Granted
|
2011-552209
|
08/23/2011
|
2012-519004
|
5707344
|
03/06/2015
|
US
|
TRANSAMINASE BIOCATALYSTS
|
Granted
|
13/604,323
|
09/05/2012
|
20120329108A1
|
8889380
|
11/18/2014
|
DE
|
TRANSAMINASE BIOCATALYSTS
|
Granted
|
10746948.8
|
09/26/2011
|
2401366
|
202010012539.4
|
12/18/2013
|
FR
|
TRANSAMINASE BIOCATALYSTS
|
Granted
|
10746948.8
|
09/26/2011
|
2401366
|
2401366
|
12/18/2013
|
ES
|
TRANSAMINASE BIOCATALYSTS
|
Granted
|
10746948.8
|
09/26/2011
|
2401366
|
2401366
|
12/18/2013
|
CH
|
TRANSAMINASE BIOCATALYSTS
|
Granted
|
10746948.8
|
09/26/2011
|
2401366
|
2401366
|
12/18/2013
|
GB
|
TRANSAMINASE BIOCATALYSTS
|
Granted
|
10746948.8
|
09/26/2011
|
2401366
|
2401366
|
12/18/2013
|
IE
|
TRANSAMINASE BIOCATALYSTS
|
Granted
|
10746948.8
|
09/26/2011
|
2401366
|
2401366
|
12/18/2013
|
IT
|
TRANSAMINASE BIOCATALYSTS
|
Granted
|
10746948.8
|
09/26/2011
|
2401366
|
2401366
|
12/18/2013
|
NL
|
TRANSAMINASE BIOCATALYSTS
|
Granted
|
10746948.8
|
09/26/2011
|
2401366
|
2401366
|
12/18/2013
|
JP
|
TRANSAMINASE BIOCATALYSTS
|
Pending
|
2014-186102
|
09/12/2014
|
|
|
|
CODEXIS ENZYME PATENTS
|
|||||||
US
|
TRANSAMINASE BIOCATALYSTS
|
Allowed
|
14/518143
|
10/20/2014
|
20150037869
|
|
|
CN
|
KETOREDUCTASE-MEDIATED STEREOSELECTIVE ROUTE TO ALPHA CHLOROALCOHOLS
|
Granted
|
201080027481.5
|
12/20/2011
|
102482648
|
ZL201080027481.5
|
12/10/2014
|
EP
|
KETOREDUCTASE-MEDIATED STEREOSELECTIVE ROUTE TO ALPHA CHLOROALCOHOLS
|
Published
|
10797576.5
|
12/22/2011
|
2446025
|
|
|
IN
|
KETOREDUCTASE-MEDIATED STEREOSELECTIVE ROUTE TO ALPHA CHLOROALCOHOLS
|
Pending
|
9363/CHENP/2011
|
12/21/2011
|
|
|
|
SG
|
KETOREDUCTASE-MEDIATED STEREOSELECTIVE ROUTE TO ALPHA CHLOROALCOHOLS
|
Granted
|
201109538-7
|
12/21/2011
|
177331
|
177331
|
08/11/2014
|
US
|
KETOREDUCTASE-MEDIATED STEREOSELECTIVE ROUTE TO ALPHA CHLOROALCOHOLS
|
Granted
|
13/378,618
|
12/15/2011
|
20120190086A1
|
8796002
|
08/05/2014
|
US
|
KETOREDUCTASE-MEDIATED STEREOSELECTIVE ROUTE TO ALPHA CHLOROALCOHOLS
|
Granted
|
14/313465
|
06/24/2014
|
20140308732
|
9029112
|
05/12/2015
|
US
|
KETOREDUCTASE-MEDIATED STEREOSELECTIVE ROUTE TO ALPHA CHLOROALCOHOLS
|
Pending
|
14/697262
|
04/27/2015
|
|
|
|
EP
|
KETOREDUCTASE POLYPEPTIDES FOR THE PREPARATION OF PHENYLEPHRINE
|
Published
|
10810597.4
|
03/15/2012
|
2467473
|
|
|
IN
|
KETOREDUCTASE POLYPEPTIDES FOR THE PREPARATION OF PHENYLEPHRINE
|
Published
|
|
03/15/2012
|
2372/CHENP/2012 A
|
|
|
US
|
KETOREDUCTASE POLYPEPTIDES FOR THE PREPARATION OF PHENYLEPHRINE
|
Allowed
|
13/390,677
|
02/15/2012
|
20120149073
|
|
|
SG
|
KETOREDUCTASE POLYPEPTIDES FOR THE PREPARATION OF PHENYLEPHRINE
|
Published
|
201201086-4
|
02/16/2012
|
178456
|
|
|
SG
|
KETOREDUCTASE POLYPEPTIDES FOR THE PREPARATION OF PHENYLEPHRINE
|
Published
|
10201405022P
|
08/19/2014
|
10201405022P
|
|
|
CODEXIS ENZYME PATENTS
|
|||||||
US
|
KETOREDUCTASE POLYPEPTIDES FOR THE PREPARATION OF PHENYLEPHRINE
|
Pending
|
14/755056
|
06/30/2015
|
|
|
|
CN
|
TRANSAMINASE REACTIONS
|
Allowed
|
201080027740.4
|
12/21/2011
|
102597226
|
|
|
EP
|
TRANSAMINASE REACTIONS
|
Published
|
10797544.3
|
12/22/2011
|
2446026
|
|
|
IN
|
TRANSAMINASE REACTIONS
|
Published
|
9683/CHENP/2011
|
12/22/2011
|
9683/CHENP/2011
|
|
|
SG
|
TRANSAMINASE REACTIONS
|
Published
|
201109536-1
|
12/21/2011
|
177329
|
|
|
US
|
TRANSAMINASE REACTIONS
|
Granted
|
13/378,963
|
04/09/2012
|
20120190085A1
|
8921079
|
12/30/2014
|
IL
|
TRANSAMINASE REACTIONS
|
Pending
|
216099
|
11/02/2011
|
|
|
|
US
|
TRANSAMINASE REACTIONS
|
Published
|
14/547339
|
11/19/2014
|
20150079640
|
|
|
US
|
BIOCATALYTIC PROCESSES FOR THE PREPARATION OF SUBSTANTIALLY STEREOMERICALLY PURE FUSED BICYCLIC PROLINE COMPOUNDS
|
Granted
|
12/490,190
|
06/23/2009
|
20100063300A1
|
8178333
|
05/15/2012
|
CN
|
BIOCATALYTIC PROCESSES FOR THE PREPARATION OF SUBSTANTIALLY STEREOMERICALLY PURE FUSED BICYCLIC PROLINE COMPOUNDS
|
Granted
|
200980133157.9
|
06/23/2009
|
102131813
|
ZL200980133157.9
|
07/30/2014
|
SG
|
BIOCATALYTIC PROCESSES FOR THE PREPARATION OF SUBSTANTIALLY STEREOMERICALLY PURE FUSED BICYCLIC PROLINE COMPOUNDS
|
Granted
|
201009300-3
|
06/23/2009
|
|
167392
|
08/15/2013
|
EP
|
BIOCATALYTIC PROCESSES FOR THE PREPARATION OF SUBSTANTIALLY STEREOMERICALLY PURE FUSED BICYCLIC PROLINE COMPOUNDS
|
Granted
|
9798485.0
|
06/23/2009
|
2307419
|
2307419
|
11/06/2013
|
IN
|
BIOCATALYTIC PROCESSES FOR THE PREPARATION OF SUBSTANTIALLY STEREOMERICALLY PURE FUSED BICYCLIC PROLINE COMPOUNDS
|
Published
|
397/CHENP/2011
|
01/19/2011
|
397/CHENP/2011 A
|
|
|
US
|
STEREOMERICALLY PURE FUSED BICYLIC PROLINE COMPOUNDS USEFUL FOR PREPARING HEPATITIS C PROTEASE INHIBITORS
|
Granted
|
13/294,930
|
11/11/2011
|
20120130087
|
8859784
|
10/14/2014
|
CODEXIS ENZYME PATENTS
|
|||||||
US
|
BIOCATALYTIC PROCESSES FOR THE PREPARATION OF STEREOMERICALLY PURE FUSED BICYCLIC PROLINE COMPOUNDS
|
Granted
|
13/436,506
|
03/30/2012
|
20120244581
|
8574876
|
11/05/2013
|
FR
|
BIOCATALYTIC PROCESSES FOR THE PREPARATION OF SUBSTANTIALLY STEREOMERICALLY PURE FUSED BICYCLIC PROLINE COMPOUNDS
|
Granted
|
9798485.0
|
06/23/2009
|
2307419
|
2307419
|
11/06/2013
|
DE
|
BIOCATALYTIC PROCESSES FOR THE PREPARATION OF SUBSTANTIALLY STEREOMERICALLY PURE FUSED BICYCLIC PROLINE COMPOUNDS
|
Granted
|
9798485.0
|
06/23/2009
|
2307419
|
602009019988.9
|
11/06/2013
|
IE
|
BIOCATALYTIC PROCESSES FOR THE PREPARATION OF SUBSTANTIALLY STEREOMERICALLY PURE FUSED BICYCLIC PROLINE COMPOUNDS
|
Granted
|
9798485.0
|
06/23/2009
|
2307419
|
2307419
|
11/06/2013
|
IT
|
BIOCATALYTIC PROCESSES FOR THE PREPARATION OF SUBSTANTIALLY STEREOMERICALLY PURE FUSED BICYCLIC PROLINE COMPOUNDS
|
Granted
|
9798485.0
|
06/23/2009
|
2307419
|
2307419
|
11/06/2013
|
NL
|
BIOCATALYTIC PROCESSES FOR THE PREPARATION OF SUBSTANTIALLY STEREOMERICALLY PURE FUSED BICYCLIC PROLINE COMPOUNDS
|
Granted
|
9798485.0
|
06/23/2009
|
2307419
|
2307419
|
11/06/2013
|
ES
|
BIOCATALYTIC PROCESSES FOR THE PREPARATION OF SUBSTANTIALLY STEREOMERICALLY PURE FUSED BICYCLIC PROLINE COMPOUNDS
|
Granted
|
9798485.0
|
06/23/2009
|
2307419
|
2307419
|
11/06/2013
|
CH
|
BIOCATALYTIC PROCESSES FOR THE PREPARATION OF SUBSTANTIALLY STEREOMERICALLY PURE FUSED BICYCLIC PROLINE COMPOUNDS
|
Granted
|
9798485.0
|
06/23/2009
|
2307419
|
2307419
|
11/06/2013
|
GB
|
BIOCATALYTIC PROCESSES FOR THE PREPARATION OF SUBSTANTIALLY STEREOMERICALLY PURE FUSED BICYCLIC PROLINE COMPOUNDS
|
Granted
|
9798485.0
|
06/23/2009
|
2307419
|
2307419
|
11/06/2013
|
US
|
KETOREDUCTASE POLYPEPTIDES AND USES THEREOF
|
Granted
|
12/545,761
|
08/21/2009
|
20100055751A1
|
8288131
|
10/16/2012
|
CODEXIS ENZYME PATENTS
|
|||||||
US
|
POLYNUCLEOTIEDES ENCODING ENGINEERED KETOREDUCTASE POLYPEPTIDES
|
Granted
|
13/610,723
|
09/11/2012
|
20130005018A1
|
8455230
|
06/04/2013
|
US
|
KETOREDUCTASE POLYPEPTIDES FOR THE PRODUCTION OF A 3-ARYL-3-HYDROXYPROPANAMINE FROM A 3-ARYL-3-KETOPROPANAMINE
|
Granted
|
12/549,154
|
08/27/2009
|
US2010-0151534-A1
|
8426178
|
04/23/2013
|
EP
|
KETOREDUCTASE POLYPEPTIDES FOR THE PRODUCTION OF A 3-ARYL-3-HYDROXYPROPANAMINE FROM A 3-ARYL-3-KETOPROPANAMINE
|
Allowed
|
9810573.7
|
08/27/2009
|
2329013
|
|
|
IN
|
KETOREDUCTASE POLYPEPTIDES FOR THE PRODUCTION OF A 3-ARYL-3-HYDROXYPROPANAMINE FROM A 3-ARYL-3-KETOPROPANAMINE
|
Published
|
2014/CHENP/2011
|
03/22/2011
|
2014/CHENP/2011 A
|
|
|
US
|
KETOREDUCTASE POLYPEPTIDES FOR THE PRODUCTION OF A 3-ARYL-3-HYDROXYPROPANAMINE FROM A 3-ARYL-3-KETOPROPANAMINE
|
Granted
|
13/796985
|
03/12/2013
|
US-2013-0177962-A1
|
8673607
|
03/18/2014
|
US
|
KETOREDUCTASE POLYPEPTIDES FOR THE STEREOSELECTIVE PRODUCTION OF (4S)-3-[(5S)-5(4-FLUOROPHENYL)-5-HYDROXYPENTANOLYL]-4PHENYL1,3-OXAZOLIDIN-2-ONE
|
Granted
|
12/545,034
|
08/20/2009
|
20100062499A1
|
8273554
|
09/25/2012
|
CN
|
KETOREDUCTASE POLYPEPTIDES FOR THE STEREOSELECTIVE PRODUCTION OF (4S)-3-[(5S)-5(4-FLUOROPHENYL)-5-HYDROXYPENTANOYL]-4PHENYL-1,3-OXAZOLIDIN-2-ONE
|
Granted
|
200980141486.8
|
04/19/2011
|
102186972
|
ZL200980141486.8
|
08/20/2014
|
CODEXIS ENZYME PATENTS
|
|||||||
SG
|
KETOREDUCTASE POLYPEPTIDES FOR THE STEREOSELECTIVE PRODUCTION OF (4S)-3-[(5S)-5(4-FLUOROPHENYL)-5-HYDROXYPENTANOYL]-4PHENYL-1,3-OXAZOLIDIN-2-ONE
|
Granted
|
201101090-7
|
02/16/2011
|
|
168980
|
08/19/2014
|
EP
|
KETOREDUCTASE POLYPEPTIDES FOR THE STEREOSELECTIVE PRODUCTION OF (4S)-3-[(5S)-5(4-FLUOROPHENYL)-5-HYDROXYPENTANOYL]-4PHENYL-1,3-OXAZOLIDIN-2-ONE
|
Granted
|
9810477.1
|
03/29/2011
|
2329014
|
2329014
|
10/22/2014
|
IN
|
KETOREDUCTASE POLYPEPTIDES FOR THE STEREOSELECTIVE PRODUCTION OF (4S)-3-[(5S)-5(4-FLUOROPHENYL)-5-HYDROXYPENTANOYL]-4PHENYL-1,3-OXAZOLIDIN-2-ONE
|
Published
|
2000/CHENP/2011
|
03/22/2011
|
2000/CHENP/2011
|
|
|
US
|
POLYNUCLEOTIDES ENCODING RECOMBINANT KETOREDUCTASE POLYPEPTIDES
|
Granted
|
13/590,882
|
08/21/2012
|
20120322136A1
|
8415126
|
04/09/2013
|
US
|
KETOREDUCTASE POLYPEPTIDES FOR THE STEREOSELECTIVE PRODUCTION OF (4S)-3-[(5S)-5(4-FLUOROPHENYL)-5-HYDROXYPENTANOLYL]-4PHENYL1,3-OXAZOLIDIN-2-ONE
|
Granted
|
13/764596
|
02/11/2013
|
US-2013-0210098-A1
|
8956840
|
02/17/2015
|
SG
|
KETOREDUCTASE POLYPEPTIDES FOR THE STEREOSELECTIVE PRODUCTION OF (4S)-3-[(5S)-5(4-FLUOROPHENYL)-5-HYDROXYPENTANOYL]-4PHENYL-1,3-OXAZOLIDIN-2-ONE
|
Published
|
10201404330V
|
07/23/2014
|
10201404330V
|
|
|
FR
|
KETOREDUCTASE POLYPEPTIDES FOR THE STEREOSELECTIVE PRODUCTION OF (4S)-3-[(5S)-5(4-FLUOROPHENYL)-5-HYDROXYPENTANOYL]-4PHENYL-1,3-OXAZOLIDIN-2-ONE
|
Granted
|
9810477.1
|
03/29/2011
|
2329014
|
2329014
|
10/22/2014
|
CODEXIS ENZYME PATENTS
|
|||||||
DE
|
KETOREDUCTASE POLYPEPTIDES FOR THE STEREOSELECTIVE PRODUCTION OF (4S)-3-[(5S)-5(4-FLUOROPHENYL)-5-HYDROXYPENTANOYL]-4PHENYL-1,3-OXAZOLIDIN-2-ONE
|
Granted
|
9810477.1
|
03/29/2011
|
2329014
|
602009027373.6
|
10/22/2014
|
HU
|
KETOREDUCTASE POLYPEPTIDES FOR THE STEREOSELECTIVE PRODUCTION OF (4S)-3-[(5S)-5(4-FLUOROPHENYL)-5-HYDROXYPENTANOYL]-4PHENYL-1,3-OXAZOLIDIN-2-ONE
|
Granted
|
9810477.1
|
03/29/2011
|
2329014
|
2329014
|
10/22/2014
|
NL
|
KETOREDUCTASE POLYPEPTIDES FOR THE STEREOSELECTIVE PRODUCTION OF (4S)-3-[(5S)-5(4-FLUOROPHENYL)-5-HYDROXYPENTANOYL]-4PHENYL-1,3-OXAZOLIDIN-2-ONE
|
Granted
|
9810477.1
|
03/29/2011
|
2329014
|
2329014
|
10/22/2014
|
SI
|
KETOREDUCTASE POLYPEPTIDES FOR THE STEREOSELECTIVE PRODUCTION OF (4S)-3-[(5S)-5(4-FLUOROPHENYL)-5-HYDROXYPENTANOYL]-4PHENYL-1,3-OXAZOLIDIN-2-ONE
|
Granted
|
9810477.1
|
03/29/2011
|
2329014
|
2329014
|
10/22/2014
|
CH
|
KETOREDUCTASE POLYPEPTIDES FOR THE STEREOSELECTIVE PRODUCTION OF (4S)-3-[(5S)-5(4-FLUOROPHENYL)-5-HYDROXYPENTANOYL]-4PHENYL-1,3-OXAZOLIDIN-2-ONE
|
Granted
|
9810477.1
|
03/29/2011
|
2329014
|
2329014
|
10/22/2014
|
GB
|
KETOREDUCTASE POLYPEPTIDES FOR THE STEREOSELECTIVE PRODUCTION OF (4S)-3-[(5S)-5(4-FLUOROPHENYL)-5-HYDROXYPENTANOYL]-4PHENYL-1,3-OXAZOLIDIN-2-ONE
|
Granted
|
9810477.1
|
03/29/2011
|
2329014
|
2329014
|
10/22/2014
|
US
|
KETOREDUCTASE POLYPEPTIDES
|
Allowed
|
14/606127
|
01/27/2015
|
20150132806
|
|
|
US
|
ENONE REDUCTASES
|
Granted
|
12/646,907
|
12/23/2009
|
20100190218A1
|
8329438
|
12/11/2012
|
EP
|
ENONE REDUCTASES
|
Granted
|
9835878.1
|
12/23/2009
|
2382308
|
2382308
|
03/04/2015
|
CODEXIS ENZYME PATENTS
|
|||||||
IN
|
ENONE REDUCTASES
|
Published
|
4505/CHENP/2011
|
12/23/2009
|
4505/CHENP/2011
|
|
|
SG
|
ENONE REDUCTASES
|
Granted
|
201104630-7
|
12/23/2009
|
172783
|
172783
|
09/03/2014
|
US
|
ENONE REDUCTASES
|
Granted
|
13/658,582
|
10/23/2012
|
US/2013-0115663-A1
|
8883475
|
11/11/2014
|
US
|
ENONE REDUCTASES
|
Allowed
|
14/504558
|
10/02/2014
|
20150031095
|
|
|
FR
|
ENONE REDUCTASES
|
Granted
|
9835878.1
|
12/23/2009
|
2382308
|
2382308
|
03/04/2015
|
DE
|
ENONE REDUCTASES
|
Granted
|
9835878.1
|
12/23/2009
|
2382308
|
602009029867.4
|
03/04/2015
|
IE
|
ENONE REDUCTASES
|
Granted
|
9835878.1
|
12/23/2009
|
2382308
|
2382308
|
03/04/2015
|
NL
|
ENONE REDUCTASES
|
Granted
|
9835878.1
|
12/23/2009
|
2382308
|
2382308
|
03/04/2015
|
CH
|
ENONE REDUCTASES
|
Granted
|
9835878.1
|
12/23/2009
|
2382308
|
2382308
|
03/04/2015
|
GB
|
ENONE REDUCTASES
|
Granted
|
9835878.1
|
12/23/2009
|
2382308
|
2382308
|
03/04/2015
|
US
|
ENONE REDUCTASES
|
Pending
|
14/800306
|
07/15/2015
|
|
|
|
US
|
RECOMBINANT HALOHYDRIN DEHALOGENASE POLYPEPTIDES
|
Granted
|
12/642,586
|
12/18/2009
|
US2010-0173372A1
|
8187856
|
05/29/2012
|
IN
|
RECOMBINANT HALOHYDRIN DEHALOGENASE POLYPEPTIDES
|
Published
|
5068/CHENP/2011
|
12/18/2009
|
5068/CHENP/2011A
|
|
|
US
|
RECOMBINANT HALOHYDRIN DEHALOGENASE POLYPEPTIDES
|
Granted
|
13/452,328
|
04/20/2012
|
20120220002
|
8580555
|
11/12/2013
|
US
|
PENICILLIN G ACYLASES
|
Granted
|
12/615,139
|
11/09/2009
|
US-2010-0143968-A1
|
8247192
|
08/21/2012
|
US
|
PENICILLIN G ACYLASES
|
Granted
|
13/542,835
|
07/06/2012
|
20120270282A1
|
8569013
|
10/29/2013
|
US
|
NITRILASE BIOCATALYSTS
|
Granted
|
13/381,155
|
12/28/2011
|
20120142063
|
8614081
|
12/24/2013
|
US
|
KETOREDUCTASE POLYPEPTIDES FOR THE PRODUCTION OF 3-ARYL-3-HYDROXYPROPANAMINE FROM A 3-ARYL-3-KETOPROPANAMINE
|
Granted
|
12/549,293
|
08/27/2009
|
US2010-0173369A1
|
8288141
|
10/16/2012
|
US
|
POLYNUCLEOTIDES ENCODING ENGINEERED KETOREDUCTASE POLYPEPTIDES
|
Granted
|
13/610,166
|
09/11/2012
|
20130005017A1
|
8877475
|
11/04/2014
|
US
|
POLYNUCLEOTIDES ENCODING ENGINEERED KETOREDUCTASE POLYPEPTIDES
|
Published
|
14/503578
|
10/01/2014
|
20150031094
|
|
|
CODEXIS ENZYME PATENTS
|
|||||||
IN
|
PROCESSES USING AMINO ACID DEHYDROGENASES AND KETOREDUCTASE-BASED COFACTOR REGENERATING SYSTEM
|
Published
|
7740/CHENP/2012
|
09/07/2012
|
7740/CHENP/2012
|
|
|
US
|
PROCESSES USING AMINO ACID DEHYDROGENASES AND KETOREDUCTASE-BASED COFACTOR REGENERATING SYSTEM
|
Pending
|
14/742215
|
06/17/2015
|
|
|
|
SG
|
STRUCTURE-ACTIVITY RELATIONSHIPS
|
Published
|
201200817-3
|
02/12/2001
|
178753
|
|
|
US
|
STRUCTURE-ACTIVITY RELATIONSHIPS
|
Published
|
13/757554
|
02/01/2013
|
2013/0165341
|
|
|
US
|
STRUCTURE-ACTIVITY RELATIONSHIPS
|
Published
|
14/662541
|
03/19/2015
|
2015/0191767
|
|
|
CN
|
KETOREDUCTASES AND USES THEREOF
|
Granted
|
200880004582.3
|
02/08/2008
|
CN 101627116A
|
ZL2008 8 0004582.3
|
07/10/2013
|
SG
|
KETOREDUCTASES AND USES THEREOF
|
Granted
|
200904674-9
|
02/08/2008
|
|
154045
|
03/30/2012
|
KR
|
KETOREDUCTASES AND USES THEREOF
|
Granted
|
10-2009-7016084
|
02/08/2008
|
|
1502634
|
03/09/2015
|
US
|
KETOREDUCTASES AND USES THEREOF
|
Granted
|
12/028,780
|
02/08/2008
|
2008/0318295
|
7820421
|
10/26/2010
|
EP
|
KETOREDUCTASES AND USES THEREOF
|
Granted
|
8725329.0
|
02/08/2008
|
2115130
|
2115130
|
08/03/2011
|
IL
|
KETOREDUCTASES AND USES THEREOF
|
Pending
|
199399
|
02/08/2008
|
|
|
|
JP
|
KETOREDUCTASES AND USES THEREOF
|
Published
|
2009-549110
|
02/08/2008
|
2010-517574
|
|
|
US
|
KETOREDUCTASES AND USES THEREOF
|
Granted
|
12/881,734
|
09/14/2010
|
2011/0165670A1
|
8071347
|
12/06/2011
|
CH
|
KETOREDUCTASES AND USES THEREOF
|
Granted
|
8725329.0
|
02/08/2008
|
2115130
|
2115130
|
08/03/2011
|
DE
|
KETOREDUCTASES AND USES THEREOF
|
Granted
|
8725329.0
|
02/08/2008
|
2115130
|
2115130
|
08/03/2011
|
FR
|
KETOREDUCTASES AND USES THEREOF
|
Granted
|
8725329.0
|
02/08/2008
|
2115130
|
2115130
|
08/03/2011
|
CODEXIS ENZYME PATENTS
|
|||||||
GB
|
KETOREDUCTASES AND USES THEREOF
|
Granted
|
8725329.0
|
02/08/2008
|
2115130
|
2115130
|
08/03/2011
|
IE
|
KETOREDUCTASES AND USES THEREOF
|
Granted
|
8725329.0
|
02/08/2008
|
2115130
|
2115130
|
08/03/2011
|
NL
|
KETOREDUCTASES AND USES THEREOF
|
Granted
|
8725329.0
|
02/08/2008
|
2115130
|
2115130
|
08/03/2011
|
US
|
KETOREDUCTASES AND USES THEREOF
|
Granted
|
13/290,773
|
11/07/2011
|
2012/0178142
|
8415127
|
04/09/2013
|
US
|
KETOREDUCTASES AND USES THEREOF
|
Granted
|
13/793158
|
03/11/2013
|
2013/0196408
|
8980605
|
03/17/2015
|
JP
|
ALCOHOL DEHYDROGENASE FOR THE STEREOSELECTIVE PRODUCTION OF HYDROXY COMPOUNDS
|
Granted
|
2007-526267
|
06/04/2005
|
|
5042831
|
07/20/2012
|
DE
|
ALCOHOL DEHYDROGENASE FOR THE STEREOSELECTIVE PRODUCTION OF HYDROXY COMPOUNDS
|
Granted
|
102004029112.8
|
06/11/2004
|
|
1763577
|
10/06/2010
|
EP
|
ALCOHOL DEHYDROGENASE FOR THE STEREOSELECTIVE PRODUCTION OF HYDROXY COMPOUNDS
|
Granted
|
5756002.1
|
06/04/2005
|
1763577
|
1763577
|
10/06/2010
|
US
|
ALCOHOL DEHYDROGENASE FOR THE STEREOSELECTIVE PRODUCTION OF HYDROXY COMPOUNDS
|
Granted
|
11/629,000
|
12/08/2006
|
2009/0162893
|
7,943,356
|
05/17/2011
|
GB
|
ALCOHOL DEHYDROGENASE FOR THE STEREOSELECTIVE PRODUCTION OF HYDROXY COMPOUNDS
|
Granted
|
5756002.1
|
06/04/2005
|
1763577
|
1763577
|
10/06/2010
|
IT
|
ALCOHOL DEHYDROGENASE FOR THE STEREOSELECTIVE PRODUCTION OF HYDROXY COMPOUNDS
|
Granted
|
5756002.1
|
06/04/2005
|
1763577
|
1763577
|
10/06/2010
|
AT
|
ALCOHOL DEHYDROGENASE FOR THE STEREOSELECTIVE PRODUCTION OF HYDROXY COMPOUNDS
|
Granted
|
5756002.1
|
06/04/2005
|
1763577
|
1763577
|
10/06/2010
|
CODEXIS ENZYME PATENTS
|
|||||||
FR
|
ALCOHOL DEHYDROGENASE FOR THE STEREOSELECTIVE PRODUCTION OF HYDROXY COMPOUNDS
|
Granted
|
5756002.1
|
06/04/2005
|
1763577
|
1763577
|
10/06/2010
|
SG
|
KETOREDUCTASE POLYPEPTIDES FOR THE STEREOSELECTIVE PRODUCTION OF (R)-3-HYDROXYTHIOLANE
|
Granted
|
201000745-8
|
08/24/2008
|
|
159008
|
09/14/2012
|
IN
|
KETOREDUCTASE POLYPEPTIDES FOR THE STEREOSELECTIVE PRODUCTION OF (R)-3-HYDROXYTHIOLANE
|
Pending
|
1624/CHENP/2010
|
08/24/2008
|
|
|
|
EP
|
KETOREDUCTASE POLYPEPTIDES FOR THE STEREOSELECTIVE PRODUCTION OF (R)-3-HYDROXYTHIOLANE
|
Granted
|
8798570.1
|
08/24/2008
|
2195443
|
2195443
|
01/07/2015
|
CN
|
KETOREDUCTASE POLYPEPTIDES FOR THE STEREOSELECTIVE PRODUCTION OF (R)-3-HYDROXYTHIOLANE
|
Granted
|
200880104011.7
|
08/24/2008
|
101784669
|
ZL200880104011.7
|
02/18/2015
|
US
|
KETOREDUCTASE POLYPEPTIDES FOR THE STEREOSELECTIVE PRODUCTION OF (R)-3-HYDROXYTHIOLANE
|
Granted
|
12/197,286
|
08/24/2008
|
2009/0093031
|
7977078
|
07/12/2011
|
US
|
KETOREDUCTASE POLYPEPTIDES FOR THE PRODUCTION OF (R)-3-HYDROXYTHIOLANE
|
Granted
|
13/110,789
|
05/18/2011
|
2011/0217754
|
8,227,229
|
07/24/2012
|
US
|
KETOREDUCTASE POLYPEPTIDES FOR THE PRODUCTION OF (R)-3-HYDROXYTHIOLANE
|
Granted
|
13/525,048
|
06/15/2012
|
2012/0276599A1
|
8962285
|
02/24/2015
|
DE
|
KETOREDUCTASE POLYPEPTIDES FOR THE STEREOSELECTIVE PRODUCTION OF (R)-3-HYDROXYTHIOLANE
|
Granted
|
8798570.1
|
08/24/2008
|
2195443
|
602008036257.4
|
01/07/2015
|
FR
|
KETOREDUCTASE POLYPEPTIDES FOR THE STEREOSELECTIVE PRODUCTION OF (R)-3-HYDROXYTHIOLANE
|
Granted
|
8798570.1
|
08/24/2008
|
2195443
|
2195443
|
01/07/2015
|
CODEXIS ENZYME PATENTS
|
|||||||
IE
|
KETOREDUCTASE POLYPEPTIDES FOR THE STEREOSELECTIVE PRODUCTION OF (R)-3-HYDROXYTHIOLANE
|
Granted
|
8798570.1
|
08/24/2008
|
2195443
|
2195443
|
01/07/2015
|
NL
|
KETOREDUCTASE POLYPEPTIDES FOR THE STEREOSELECTIVE PRODUCTION OF (R)-3-HYDROXYTHIOLANE
|
Granted
|
8798570.1
|
08/24/2008
|
2195443
|
2195443
|
01/07/2015
|
CH
|
KETOREDUCTASE POLYPEPTIDES FOR THE STEREOSELECTIVE PRODUCTION OF (R)-3-HYDROXYTHIOLANE
|
Granted
|
8798570.1
|
08/24/2008
|
2195443
|
2195443
|
01/07/2015
|
GB
|
KETOREDUCTASE POLYPEPTIDES FOR THE STEREOSELECTIVE PRODUCTION OF (R)-3-HYDROXYTHIOLANE
|
Granted
|
8798570.1
|
08/24/2008
|
2195443
|
2195443
|
01/07/2015
|
US
|
KETOREDUCTASE POLYPEPTIDES FOR THE PRODUCTION OF (R)-3-HYDROXYTHIOLANE
|
Published
|
14/597996
|
01/15/2015
|
2015/0125910
|
|
|
CN
|
KETOREDUCTASE POLYPEPTIDES FOR THE REDUCTION OF ACETOPHENONES
|
Granted
|
200880115770.3
|
09/13/2008
|
101855342
|
ZL 2008 8 0115770.3
|
07/10/2013
|
JP
|
KETOREDUCTASE POLYPEPTIDES FOR THE REDUCTION OF ACETOPHENONES
|
Published
|
2010-525057
|
09/13/2008
|
2010-538657
|
|
|
US
|
KETOREDUCTASE POLYPEPTIDES FOR THE REDUCTION OF ACETOPHENONES
|
Granted
|
12/210,195
|
09/13/2008
|
2009/0191605
|
8748143
|
06/10/2014
|
IN
|
KETOREDUCTASE POLYPEPTIDES FOR THE REDUCTION OF ACETOPHENONES
|
Pending
|
2039/CHENP/2010
|
09/13/2008
|
|
|
|
SG
|
KETOREDUCTASE POLYPEPTIDES FOR THE REDUCTION OF ACETOPHENONES
|
Granted
|
201001576-6
|
09/13/2008
|
|
159828
|
04/13/2012
|
EP
|
KETOREDUCTASE POLYPEPTIDES FOR THE REDUCTION OF ACETOPHENONES
|
Granted
|
8830789.7
|
09/13/2008
|
2198018
|
2198018
|
11/20/2013
|
CODEXIS ENZYME PATENTS
|
|||||||
KR
|
KETOREDUCTASE POLYPEPTIDES FOR THE REDUCTION OF ACETOPHENONES
|
Pending
|
10-2010-7007675
|
09/13/2008
|
|
|
|
US
|
KETOREDUCTASE POLYPEPTIDES FOR THE REDUCTION OF ACETOPHENONES
|
Granted
|
13/682,600
|
11/20/2012
|
2013/0078692
|
8512973
|
08/20/2013
|
US
|
KETOREDUCTASE POLYPEPTIDES FOR THE REDUCTION OF ACETOPHENONES
|
Granted
|
13/970284
|
08/19/2013
|
2013/0344552
|
8852909
|
10/07/2014
|
DE
|
KETOREDUCTASE POLYPEPTIDES FOR THE REDUCTION OF ACETOPHENONES
|
Granted
|
8830789.7
|
09/13/2008
|
2198018
|
602008028883.8
|
11/20/2013
|
FR
|
KETOREDUCTASE POLYPEPTIDES FOR THE REDUCTION OF ACETOPHENONES
|
Granted
|
8830789.7
|
09/13/2008
|
2198018
|
2198018
|
11/20/2013
|
CH
|
KETOREDUCTASE POLYPEPTIDES FOR THE REDUCTION OF ACETOPHENONES
|
Granted
|
8830789.7
|
09/13/2008
|
2198018
|
2198018
|
11/20/2013
|
GB
|
KETOREDUCTASE POLYPEPTIDES FOR THE REDUCTION OF ACETOPHENONES
|
Granted
|
8830789.7
|
09/13/2008
|
2198018
|
2198018
|
11/20/2013
|
IE
|
KETOREDUCTASE POLYPEPTIDES FOR THE REDUCTION OF ACETOPHENONES
|
Granted
|
8830789.7
|
09/13/2008
|
2198018
|
2198018
|
11/20/2013
|
NL
|
KETOREDUCTASE POLYPEPTIDES FOR THE REDUCTION OF ACETOPHENONES
|
Granted
|
8830789.7
|
09/13/2008
|
2198018
|
2198018
|
11/20/2013
|
US
|
KETOREDUCTASE POLYPEPTIDES FOR THE REDUCTION OF ACETOPHENONES
|
Published
|
14/501416
|
09/30/2014
|
2015/0017695
|
|
|
JP
|
KETOREDUCTASE POLYPEPTIDES FOR THE REDUCTION OF ACETOPHENONES
|
Published
|
2015-21874
|
02/06/2015
|
2015-91269
|
|
|
SG
|
KETOREDUCTASE POLYPEPTIDES AND USES THEREOF
|
Granted
|
201001902-4
|
09/28/2008
|
|
160022
|
07/31/2013
|
US
|
KETOREDUCTASE POLYPEPTIDES AND USES THEREOF
|
Granted
|
12/240,986
|
09/29/2008
|
2009/0155863
|
8088610
|
01/03/2012
|
IN
|
BIOCATALYSTS AND METHODS FOR THE SYNTHESIS OF (1R,2R)-2-(3,4-DIMETHOXYPHENETHOXY)CYCLOHEXANAMINE
|
Published
|
2013/CHENP/2013
|
03/13/2013
|
2013/CHENP/2013
|
|
|
US
|
BIOCATALYSTS AND METHODS FOR THE SYNTHESIS OF (1R,2R)-2-(3,4-DIMETHOXYPHENETHOXY)CYCLOHEXANAMINE
|
Granted
|
13/817295
|
03/12/2013
|
US-2013-0164794-A1
|
8932836
|
01/13/2015
|
DE
|
BIOCATALYSTS AND METHODS FOR THE SYNTHESIS OF (1R,2R)-2-(3,4-DIMETHOXYPHENETHOXY)CYCLOHEXANAMINE
|
Granted
|
11818555.2
|
04/29/2013
|
2606139
|
2606139
|
07/15/2015
|
FR
|
BIOCATALYSTS AND METHODS FOR THE SYNTHESIS OF (1R,2R)-2-(3,4-DIMETHOXYPHENETHOXY)CYCLOHEXANAMINE
|
Granted
|
11818555.2
|
04/29/2013
|
2606139
|
2606139
|
07/15/2015
|
GB
|
BIOCATALYSTS AND METHODS FOR THE SYNTHESIS OF (1R,2R)-2-(3,4-DIMETHOXYPHENETHOXY)CYCLOHEXANAMINE
|
Granted
|
11818555.2
|
04/29/2013
|
2606139
|
2606139
|
07/15/2015
|
IE
|
BIOCATALYSTS AND METHODS FOR THE SYNTHESIS OF (1R,2R)-2-(3,4-DIMETHOXYPHENETHOXY)CYCLOHEXANAMINE
|
Granted
|
11818555.2
|
04/29/2013
|
2606139
|
2606139
|
07/15/2015
|
SG
|
KETOREDUCTASE POLYPEPTIDES FOR THE PRODUCTION OF AZETIDINONE
|
Granted
|
201001989-1
|
10/01/2008
|
|
160517
|
05/05/2014
|
US
|
KETOREDUCTASE POLYPEPTIDES FOR THE PRODUCTION OF AZETIDINONE
|
Granted
|
12/243,968
|
10/01/2008
|
US2009/0162909
|
7883879
|
02/08/2011
|
EP
|
KETOREDUCTASE POLYPEPTIDES FOR THE PRODUCTION OF AZETIDINONE
|
Granted
|
8836133.2
|
10/01/2008
|
2205727
|
2205727
|
06/24/2015
|
IL
|
KETOREDUCTASE POLYPEPTIDES FOR THE PRODUCTION OF AZETIDINONE
|
Granted
|
204379
|
10/01/2008
|
|
204379
|
10/01/2014
|
JP
|
KETOREDUCTASE POLYPEPTIDES FOR THE PRODUCTION OF AZETIDINONE
|
Granted
|
2010-527257
|
10/01/2008
|
|
5646328
|
11/14/2014
|
IN
|
KETOREDUCTASE POLYPEPTIDES FOR THE PRODUCTION OF AZETIDINONE
|
Pending
|
2450/CHENP/2010
|
10/01/2008
|
|
|
|
US
|
KETOREDUCTASE POLYPEPTIDES FOR THE PRODUCTION OF AZETIDINONE
|
Granted
|
12/977,825
|
12/23/2010
|
20110159567A1
|
8257952
|
09/04/2012
|
US
|
KETOREDUCTASE POLYPEPTIDES FOR THE PRODUCTION OF AZETIDINONE
|
Granted
|
13/569,900
|
08/08/2012
|
20130034895
|
8470572
|
06/25/2013
|
US
|
KETOREDUCTASE POLYPEPTIDES FOR THE PRODUCTION OF AZETIDINONE
|
Granted
|
13/925096
|
06/24/2013
|
2014/0057330
|
8980606
|
03/17/2015
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
|
|
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
|
|
|
FR
|
KETOREDUCTASE POLYPEPTIDES FOR THE PRODUCTION OF AZETIDINONE
|
Granted
|
8836133.2
|
10/01/2008
|
2205727
|
2205727
|
06/24/2015
|
DE
|
KETOREDUCTASE POLYPEPTIDES FOR THE PRODUCTION OF AZETIDINONE
|
Granted
|
8836133.2
|
10/01/2008
|
2205727
|
602008038717.8
|
06/24/2015
|
HU
|
KETOREDUCTASE POLYPEPTIDES FOR THE PRODUCTION OF AZETIDINONE
|
Granted
|
8836133.2
|
10/01/2008
|
2205727
|
2205727
|
06/24/2015
|
IT
|
KETOREDUCTASE POLYPEPTIDES FOR THE PRODUCTION OF AZETIDINONE
|
Granted
|
8836133.2
|
10/01/2008
|
2205727
|
2205727
|
06/24/2015
|
NL
|
KETOREDUCTASE POLYPEPTIDES FOR THE PRODUCTION OF AZETIDINONE
|
Granted
|
8836133.2
|
10/01/2008
|
2205727
|
2205727
|
06/24/2015
|
SI
|
KETOREDUCTASE POLYPEPTIDES FOR THE PRODUCTION OF AZETIDINONE
|
Granted
|
8836133.2
|
10/01/2008
|
2205727
|
2205727
|
06/24/2015
|
ES
|
KETOREDUCTASE POLYPEPTIDES FOR THE PRODUCTION OF AZETIDINONE
|
Granted
|
8836133.2
|
10/01/2008
|
2205727
|
2205727
|
06/24/2015
|
GB
|
KETOREDUCTASE POLYPEPTIDES FOR THE PRODUCTION OF AZETIDINONE
|
Granted
|
8836133.2
|
10/01/2008
|
2205727
|
2205727
|
06/24/2015
|
EP
|
BIOCATALYTIC PROCESS FOR PREPARING ESLICARBAZEPINE AND ANALOGS THEREOF
|
Published
|
12771861.7
|
11/06/2013
|
2697662
|
|
|
IN
|
BIOCATALYTIC PROCESS FOR PREPARING ESLICARBAZEPINE AND ANALOGS THEREOF
|
Published
|
7967/CHENP/2013
|
10/01/2013
|
7967/CHENP/2013
|
|
|
US
|
BIOCATALYTIC PROCESS FOR PREPARING ESLICARBAZEPINE AND ANALOGS THEREOF
|
Allowed
|
14/110964
|
12/05/2013
|
20140199735
|
|
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
|
|
|
US
|
BIOCATALYSTS AND METHODS FOR HYDROXYLATION OF CHEMICAL COMPOUNDS
|
Published
|
14/399034
|
11/05/2014
|
20150118719
|
|
|
CN
|
BIOCATALYSTS AND METHODS FOR HYDROXYLATION OF CHEMICAL COMPOUNDS
|
Published
|
2013800362951
|
01/07/2015
|
104428412
|
|
|
EP
|
BIOCATALYSTS AND METHODS FOR HYDROXYLATION OF CHEMICAL COMPOUNDS
|
Published
|
13788385.6
|
12/08/2014
|
2847327
|
|
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
|
|
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
|
|
|
EP
|
BIOCATALYSTS AND METHODS FOR THE SYNTHESIS OF SUBSTITUTED LACTAMS
|
Published
|
12769209.3
|
03/31/2014
|
2753640
|
|
|
US
|
BIOCATALYSTS AND METHODS FOR THE SYNTHESIS OF SUBSTITUTED LACTAMS
|
Allowed
|
14/342713
|
03/04/2014
|
2014/0342412
|
|
|
CN
|
BIOCATALYSTS AND METHODS FOR THE SYNTHESIS OF SUBSTITUTED LACTAMS
|
Published
|
2012800547455
|
05/07/2014
|
103998461
|
|
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
|
|
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
|
|
|
US
|
BIOCATALYSTS AND METHODS FOR SYNTHESIZING DERIVATIVES OF TRYPTAMINE AND TRYPTAMINE ANALOGS
|
Allowed
|
14/386082
|
09/18/2014
|
20150072383
|
|
|
US
|
ENGINEERED IMINE REDUCTASES AND METHODS FOR THE REDUCTIVE AMINATION OF KETONE AND AMINE COMPOUNDS
|
Published
|
13/890944
|
05/09/2013
|
20130302859A1
|
|
|
EP
|
ENGINEERED IMINE REDUCTASES AND METHODS FOR THE REDUCTIVE AMINATION OF KETONE AND AMINE COMPOUNDS
|
Published
|
13724127.9
|
12/08/2014
|
2847214
|
|
|
CN
|
ENGINEERED IMINE REDUCTASES AND METHODS FOR THE REDUCTIVE AMINATION OF KETONE AND AMINE COMPOUNDS
|
Published
|
2013800370394
|
01/12/2015
|
104428313
|
|
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
|
|
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
|
|
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
|
|
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
|
|
|
[***]
|
[***]
|
[***]
|
|
[***]
|
|
|
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
|
|
|
WO
|
ENGINEERED TRANSAMINASE POLYPEPTIDES FOR INDUSTRIAL BIOCATALYSIS
|
Published
|
PCT/US2014/018005
|
02/24/2014
|
WO2014/133960
|
|
|
US
|
ENGINEERED IMINE REDUCTASES AND METHODS FOR THE REDUCTIVE AMINATION OF KETONE AND AMINE COMPOUNDS
|
Published
|
14/539690
|
11/12/2014
|
20150132807
|
|
|
WO
|
ENGINEERED IMINE REDUCTASES AND METHODS FOR THE REDUCTIVE AMINATION OF KETONE AND AMINE COMPOUNDS
|
Published
|
PCT/US2014/065259
|
11/12/2014
|
WO2015/073555
|
|
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
|
|
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
|
|
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
|
|
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
|
|
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
|
|
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
|
|
|
IN
|
IMPROVED KETOREDUCTASE POLYPEPTIDES AND RELATED POLYNUCLEOTIDES
|
Granted
|
514/CHENP/2006
|
08/11/2004
|
|
239120
|
03/09/2010
|
SG
|
IMPROVED KETOREDUCTASE POLYPEPTIDES AND RELATED POLYNUCLEOTIDES
|
Granted
|
200600860-1
|
08/11/2004
|
|
119648
|
12/31/2008
|
US
|
KETOREDUCTASE POLYPEPTIDES AND RELATED POLYNUCLEOTIDES
|
Granted
|
10/916,311
|
08/11/2004
|
20060195947A1
|
7629157
|
12/08/2009
|
US
|
KETOREDUCTASE POLYPEPTIDES AND RELATED POLYNUCLEOTIDES
|
Granted
|
12/576,195
|
10/08/2009
|
20100028972A1
|
7833767
|
11/16/2010
|
EP
|
ENZYMATIC PROCESSES FOR THE PRODUCTION OF 4-SUBSTITUTED 3-HYDROXYBUTYRIC ACID DERIVATIVES
|
Granted
|
3785237.3
|
08/11/2003
|
1537222
|
1537222
|
03/09/2011
|
US
|
ENZYMATIC PROCESSES FOR THE PRODUCTION OF 4-SUBSTITUTED 3-HYDROXYBUTYRIC ACID DERIVATIVES
|
Granted
|
11/502,745
|
08/10/2006
|
20070161094A1
|
7807423
|
10/05/2010
|
US
|
ENZYMATIC PROCESSES FOR THE PRODUCTION OF 4-SUBSTITUTED 3-HYDROXYBUTYRIC ACID DERIVATIVES AND VICINAL CYANO, HYDROXY SUBSTITUTED CARBOXYLIC ACID ESTERS
|
Granted
|
10/782,258
|
02/18/2004
|
US 2004-0214297 A1
|
7132267
|
11/07/2006
|
US
|
ENZYMATIC PROCESSES FOR THE PRODUCTION OF 4-SUBSTITUTED 3-HYDROXYBUTYRIC ACID DERIVATIVES
|
Granted
|
10/639,159
|
08/11/2003
|
US 2004-0137585 A1
|
7125693
|
10/24/2006
|
IN
|
ENZYMATIC PROCESSES FOR THE PRODUCTION OF 4-SUBSTITUTED 3-HYDROXYBUTYR1C ACID DERIVATIVES
|
Granted
|
158/CHENP/2005
|
08/11/2003
|
|
220964
|
06/11/2008
|
SG
|
ENZYMATIC PROCESSES FOR THE PRODUCTION OF 4-SUBSTITUTED 3-HYDROXYBUTYRIC ACID DERIVATIVES
|
Granted
|
2005007634-8
|
08/11/2003
|
|
109875
|
08/31/2007
|
SG
|
ENZYMATIC PROCESSES FOR THE PRODUCTION OF 4-SUBSTITUTED 3-RYDROXYBUTYRIC ACID DERIVATIVES AND VICINAL CYANO, HYDROXY SUBSTITUTED CARBOXYLIC ACID ESTERS
|
Granted
|
200600847-8
|
02/18/2004
|
|
119636
|
02/29/2008
|
JP
|
ENZYMATIC PROCESSES FOR THE PRODUCTION OF 4-SUBSTITUTED 3-HYDROXYBUTYRIC ACID DERIVATIVES
|
Granted
|
2004-528083
|
08/11/2003
|
2005-535330
|
4578240
|
09/03/2010
|
HK
|
ENZYMATIC PROCESSES FOR THE PRODUCTION OF 4-SUBSTITUTED 3-HYDROXYBUTYRIC ACID DERIVATIVES
|
Granted
|
5108017.7
|
08/11/2003
|
|
HK1074059
|
09/09/2011
|
FR
|
ENZYMATIC PROCESSES FOR THE PRODUCTION OF 4-SUBSTITUTED 3-HYDROXYBUTYRIC ACID DERIVATIVES
|
Granted
|
3785237.3
|
08/11/2003
|
1537222
|
1537222
|
03/09/2011
|
DE
|
ENZYMATIC PROCESSES FOR THE PRODUCTION OF 4-SUBSTITUTED 3-HYDROXYBUTYRIC ACID DERIVATIVES
|
Granted
|
3785237.3
|
08/11/2003
|
1537222
|
1537222
|
03/09/2011
|
IE
|
ENZYMATIC PROCESSES FOR THE PRODUCTION OF 4-SUBSTITUTED 3-HYDROXYBUTYRIC ACID DERIVATIVES
|
Granted
|
3785237.3
|
08/11/2003
|
1537222
|
1537222
|
03/09/2011
|
NL
|
ENZYMATIC PROCESSES FOR THE PRODUCTION OF 4-SUBSTITUTED 3-HYDROXYBUTYRIC ACID DERIVATIVES
|
Granted
|
3785237.3
|
08/11/2003
|
1537222
|
1537222
|
03/09/2011
|
GB
|
ENZYMATIC PROCESSES FOR THE PRODUCTION OF 4-SUBSTITUTED 3-HYDROXYBUTYRIC ACID DERIVATIVES
|
Granted
|
3785237.3
|
08/11/2003
|
1537222
|
1537222
|
03/09/2011
|
SG
|
IMPROVED GLUCOSE DEHYDROGENASE POLYPEPTIDES AND RELATED POLYNUCLEOTIDES
|
Granted
|
200600859-3
|
08/11/2004
|
|
119647
|
02/27/2009
|
US
|
IMPROVED GLUCOSE DEHYDROGENASE POLYPEPTIDES AND RELATED POLYNUCLEOTIDES
|
Granted
|
12/790,784
|
05/28/2010
|
US20100304459
|
7939309
|
05/10/2011
|
IN
|
IMPROVED GLUCOSE DEHYDROGENASE POLYPEPTIDES AND RELATED POLYNUCLEOTIDES
|
Granted
|
521/CHENP/2006
|
08/11/2004
|
|
239922
|
04/09/2010
|
AU
|
IMPROVED GLUCOSE DEHYDROGENASE POLYPEPTIDES AND RELATED POLYNUCLEOTIDES
|
Granted
|
2004288134
|
08/11/2004
|
|
2004288134
|
04/01/2010
|
US
|
IMPROVED GLUCOSE DEHYDROGENASE POLYPEPTIDES AND RELATED POLYNUCLEOTIDES
|
Granted
|
10/915,927
|
08/11/2004
|
20050095619A1
|
7816111
|
10/19/2010
|
EP
|
IMPROVED GLUCOSE DEHYDROGENASE POLYPEPTIDES AND RELATED POLYNUCLEOTIDES
|
Granted
|
4816807.4
|
08/11/2004
|
1660648
|
1660648
|
10/09/2013
|
FR
|
IMPROVED GLUCOSE DEHYDROGENASE POLYPEPTIDES AND RELATED POLYNUCLEOTIDES
|
Granted
|
4816807.4
|
08/11/2004
|
1660648
|
1660648
|
10/09/2013
|
DE
|
IMPROVED GLUCOSE DEHYDROGENASE POLYPEPTIDES AND RELATED POLYNUCLEOTIDES
|
Granted
|
4816807.4
|
08/11/2004
|
1660648
|
602004043547.3
|
10/09/2013
|
IE
|
IMPROVED GLUCOSE DEHYDROGENASE POLYPEPTIDES AND RELATED POLYNUCLEOTIDES
|
Granted
|
4816807.4
|
08/11/2004
|
1660648
|
1660648
|
10/09/2013
|
NL
|
IMPROVED GLUCOSE DEHYDROGENASE POLYPEPTIDES AND RELATED POLYNUCLEOTIDES
|
Granted
|
4816807.4
|
08/11/2004
|
1660648
|
1660648
|
10/09/2013
|
CH
|
IMPROVED GLUCOSE DEHYDROGENASE POLYPEPTIDES AND RELATED POLYNUCLEOTIDES
|
Granted
|
4816807.4
|
08/11/2004
|
1660648
|
1660648
|
10/09/2013
|
GB
|
IMPROVED GLUCOSE DEHYDROGENASE POLYPEPTIDES AND RELATED POLYNUCLEOTIDES
|
Granted
|
4816807.4
|
08/11/2004
|
1660648
|
1660648
|
10/09/2013
|
US
|
HALOHYDRIN DEHALOGENASES AND RELATED POLYNUCLEOTIDES
|
Granted
|
12/573,824
|
10/05/2009
|
US2010-0167345A1
|
8101395
|
01/24/2012
|
US
|
HALOHYDRIN DEHALOGENASES AND RELATED POLYNUCLEOTIDES
|
Granted
|
10/917,179
|
08/11/2004
|
20050153417A1
|
7824898
|
11/02/2010
|
IN
|
IMPROVED HALOHYDRIN DEHALOGENASES AND RELATED POLYNUCLEOTIDES
|
Granted
|
519/CHENP/2006
|
08/11/2004
|
|
239852
|
04/06/2010
|
SG
|
IMPROVED HALOHYDRIN DEHALOGENASES AND RELATED POLYNUCLEOTIDES
|
Granted
|
200808477-4
|
11/14/2008
|
148180
|
148180
|
01/30/2014
|
US
|
IMPROVED HALOHYDRIN DEHALOGENASES AND RELATED POLYNUCLEOTIDES
|
Granted
|
11/266,747
|
11/02/2005
|
20060099700A1
|
7588928
|
09/15/2009
|
US
|
IMPROVED HALOHYDRIN DEHALOGENASES AND RELATED POLYNUCLEOTIDES
|
Granted
|
11/067,323
|
02/23/2005
|
US 2005-0272064 A1
|
7541171
|
06/02/2009
|
US
|
IMPROVED HALOHYDRIN DEHALOGENASES AND RELATED POLYNUCLEOTIDES
|
Granted
|
12/505,374
|
07/17/2009
|
20090298125A1
|
8252554
|
08/28/2012
|
US
|
HALOHYDRIN DEHALOGENASES AND RELATED POLYNUCLEOTIDES
|
Granted
|
13/349,514
|
01/12/2012
|
US20120208259A1
|
8535910
|
09/17/2013
|
US
|
ALANINE 2,3-AMINOMUTASES AND RELATED POLYNUCLEOTIDES
|
Granted
|
11/919,271
|
03/20/2009
|
20100099143A1
|
7790432
|
09/07/2010
|
IN
|
COMPOSITIONS AND METHODS FOR PRODUCING STEREOISOMERICALLY PURE STATINS AND SYNTHETIC INTERMEDIATES THEREFOR
|
Pending
|
2322/CHENP/2009
|
10/01/2007
|
|
|
|
SG
|
COMPOSITIONS AND METHODS FOR PRODUCING STEREOISOMERICALLY PURE STATINS AND SYNTHETIC INTERMEDIATES THEREFOR
|
Granted
|
200901677-5
|
10/01/2010
|
|
150849
|
01/30/2014
|
EP
|
COMPOSITIONS AND METHODS FOR PRODUCING STEREOISOMERICALLY PURE STATINS AND SYNTHETIC INTERMEDIATES THEREFOR
|
Granted
|
7843631.8
|
10/01/2007
|
2066788
|
2066788
|
07/23/2014
|
CN
|
COMPOSITIONS AND METHODS FOR PRODUCING STEREOISOMERICALLY PURE STATINS AND SYNTHETIC INTERMEDIATES THEREFOR
|
Allowed
|
200780036841.6
|
10/01/2007
|
101528917
|
|
|
US
|
COMPOSITIONS AND METHODS FOR PRODUCING STEREOISOMERICALLY PURE STATINS AND SYNTHETIC INTERMEDIATES THEREFOR
|
Granted
|
11/865696
|
10/01/2007
|
248539
|
7879585
|
02/01/2011
|
US
|
COMPOSITIONS AND METHODS FOR PRODUCING STEREOISOMERICALLY PURE STATINS AND SYNTHETIC INTERMEDIATES THEREFOR
|
Granted
|
12/978,022
|
12/23/2010
|
US20110195465A1
|
8273547
|
09/25/2012
|
US
|
POLYNUCLEOTIDES ENCODING KETOREDUCTASES FOR PRODUCING STEREOISOMERICALLY PURE STATINS AND SYNTHETIC INTERMEDIATES THEREFOR
|
Granted
|
13/571,248
|
08/09/2012
|
20130040364
|
8617864
|
12/31/2013
|
FR
|
COMPOSITIONS AND METHODS FOR PRODUCING STEREOISOMERICALLY PURE STATINS AND SYNTHETIC INTERMEDIATES THEREFOR
|
Granted
|
7843631.8
|
10/01/2007
|
2066788
|
2066788
|
07/23/2014
|
DE
|
COMPOSITIONS AND METHODS FOR PRODUCING STEREOISOMERICALLY PURE STATINS AND SYNTHETIC INTERMEDIATES THEREFOR
|
Granted
|
7843631.8
|
10/01/2007
|
2066788
|
602007037820.6
|
07/23/2014
|
GB
|
COMPOSITIONS AND METHODS FOR PRODUCING STEREOISOMERICALLY PURE STATINS AND SYNTHETIC INTERMEDIATES THEREFOR
|
Granted
|
7843631.8
|
10/01/2007
|
2066788
|
2066788
|
07/23/2014
|
US
|
ENZYMATIC CONVERSION OF EPDXIDES
|
Granted
|
11/833,933
|
08/03/2007
|
US2008/0220485
|
7695942
|
04/13/2010
|
CODEXIS MAYFLOWER PATENTS
|
|||||||
Country
|
Application Title
|
Application Status
|
Application Number
|
Filing Date
|
Publication Number
|
Patent Number
|
Issue Date
|
US
|
EVOLVING CELLULAR DNA UPTAKE BY RECURSIVE SEQUENCE RECOMBINATION
|
GRANTED
|
08/792409
|
02/03/1997
|
|
6096548
|
08/01/2000
|
US
|
EVOLVING CELLULAR DNA UPTAKE BY RECURSIVE SEQUENCE RECOMBINATION
|
GRANTED
|
09/430927
|
11/01/1999
|
|
6358742
|
03/19/2002
|
US
|
METHOD FOR PRODUCING POLYNUCLEOTIDES WITH DESIRED PROPERTIES
|
GRANTED
|
09/333762
|
06/15/1999
|
|
6337186
|
01/08/2002
|
US
|
HIGH THROUGHPUT MASS SPECTROMETRY
|
GRANTED
|
09/502,283
|
02/11/2000
|
|
7384387
|
06/10/2008
|
US
|
METHODS OF MAKING CHARACTER STRINGS, POLYNUCLEOTIDES & POLYPEPTIDES HAVING DESIRED CHARACTERISTICS
|
GRANTED
|
11/339090
|
01/24/2006
|
142950
|
7620502
|
11/17/2009
|
US
|
METHODS OF MAKING CHARACTER STRINGS, POLYNUCLEOTIDES & POLYPEPTIDES HAVING DESIRED CHARACTERISTICS
|
GRANTED
|
11/975638
|
10/18/2007
|
50782
|
7853410
|
12/14/2010
|
US
|
METHODS OF MAKING CHARACTER STRINGS, POLYNUCLEOTIDES & POLYPEPTIDES HAVING DESIRED CHARACTERISTICS
|
GRANTED
|
12/557463
|
09/10/2009
|
56385
|
7957912
|
06/07/2011
|
CODEXIS MAYFLOWER PATENTS
|
|||||||
US
|
METHODS OF MAKING CHARACTER STRINGS, POLYNUCLEOTIDES & POLYPEPTIDES HAVING DESIRED CHARACTERISTICS
|
GRANTED
|
11/982405
|
10/31/2007
|
318795
|
7904249
|
03/08/2011
|
US
|
METHODS OF MAKING CHARACTER STRINGS, POLYNUCLEOTIDES & POLYPEPTIDES HAVING DESIRED CHARACTERISTICS
|
GRANTED
|
09/618579
|
07/18/2000
|
|
7024312
|
04/04/2006
|
US
|
METHODS OF MAKING CHARACTER STRINGS, POLYNUCLEOTIDES & POLYPEPTIDES HAVING DESIRED CHARACTERISTICS
|
GRANTED
|
09/539486
|
03/30/2000
|
|
7058515
|
06/06/2006
|
US
|
METHODS OF MAKING CHARACTER STRINGS, POLYNUCLEOTIDES & POLYPEPTIDES HAVING DESIRED CHARACTERISTICS
|
GRANTED
|
09/494282
|
01/18/2000
|
183934
|
6917882
|
07/12/2005
|
US
|
METHODS OF MAKING CHARACTER STRINGS, POLYNUCLEOTIDES & POLYPEPTIDES HAVING DESIRED CHARACTERISTICS
|
GRANTED
|
11/075231
|
03/07/2005
|
191688
|
7421347
|
09/02/2008
|
US
|
OLIGONUCLEOTIDE MEDIATED NUCLEIC ACID RECOMBINATION
|
GRANTED
|
09/626929
|
07/27/2000
|
|
6319714
|
11/20/2001
|
GB
|
OLIGONUCLEOTIDE MEDIATED NUCLEIC ACID RECOMBINATION
|
GRANTED
|
909923.5
|
01/18/2000
|
1072010
|
1072010
|
04/21/2010
|
US
|
OLIGONUCLEOTIDE MEDIATED NUCLEIC ACID RECOMBINATION
|
GRANTED
|
09/694863
|
10/23/2000
|
|
6521453
|
02/18/2003
|
US
|
OLIGONUCLEOTIDE MEDIATED NUCLEIC ACID RECOMBINATION
|
GRANTED
|
11/987555
|
11/30/2007
|
171668
|
8029988
|
10/04/2011
|
US
|
OLIGONUCLEOTIDE MEDIATED NUCLEIC ACID RECOMBINATION
|
GRANTED
|
12/557829
|
09/11/2009
|
184627
|
8058001
|
11/15/2011
|
CODEXIS MAYFLOWER PATENTS
|
|||||||
CA
|
OLIGONUCLEOTIDE MEDIATED NUCLEIC ACID RECOMBINATION
|
GRANTED
|
2320697
|
01/18/2000
|
2320697
|
2320697
|
11/18/2014
|
US
|
OLIGONUCLEOTIDE MEDIATED NUCLEIC ACID RECOMBINATION
|
GRANTED
|
09/626595
|
07/27/2000
|
|
6479652
|
11/12/2002
|
EP
|
OLIGONUCLEOTIDE MEDIATED NUCLEIC ACID RECOMBINATION
|
GRANTED
|
909923.5
|
01/18/2000
|
1072010
|
1072010
|
04/21/2010
|
EP
|
OLIGONUCLEOTIDE MEDIATED NUCLEIC ACID RECOMBINATION
|
ALLOWED
|
10075153.6
|
01/18/2000
|
2253704
|
|
|
BE
|
OLIGONUCLEOTIDE MEDIATED NUCLEIC ACID RECOMBINATION
|
GRANTED
|
909923.5
|
01/18/2000
|
1072010
|
1072010
|
04/21/2010
|
DK
|
OLIGONUCLEOTIDE MEDIATED NUCLEIC ACID RECOMBINATION
|
GRANTED
|
909923.5
|
01/18/2000
|
1072010
|
1072010
|
04/21/2010
|
FR
|
OLIGONUCLEOTIDE MEDIATED NUCLEIC ACID RECOMBINATION
|
GRANTED
|
909923.5
|
01/18/2000
|
1072010
|
1072010
|
04/21/2010
|
DE
|
OLIGONUCLEOTIDE MEDIATED NUCLEIC ACID RECOMBINATION
|
GRANTED
|
909923.5
|
01/18/2000
|
1072010
|
1072010
|
04/21/2010
|
NL
|
OLIGONUCLEOTIDE MEDIATED NUCLEIC ACID RECOMBINATION
|
GRANTED
|
909923.5
|
01/18/2000
|
1072010
|
1072010
|
04/21/2010
|
CH
|
OLIGONUCLEOTIDE MEDIATED NUCLEIC ACID RECOMBINATION
|
GRANTED
|
909923.5
|
01/18/2000
|
1072010
|
1072010
|
04/21/2010
|
US
|
RECOMBINATION OF INSERTION MODIFIED NUCLEIC ACIDS
|
GRANTED
|
09/723520
|
11/27/2000
|
|
6413745
|
07/02/2002
|
US
|
RECOMBINATION OF INSERTION MODIFIED NUCLEIC ACIDS
|
GRANTED
|
09/723473
|
11/27/2000
|
|
6358740
|
03/19/2002
|
US
|
RECOMBINATION OF INSERTION MODIFIED NUCLEIC ACIDS
|
GRANTED
|
09/517933
|
03/03/2000
|
|
6365377
|
04/02/2002
|
US
|
OPTIMIZATION OF CROSSOVER POINTS FOR DIRECTED EVOLUTION
|
GRANTED
|
12/557434
|
09/10/2009
|
70192
|
8108150
|
01/31/2012
|
US
|
OPTIMIZATION OF CROSSOVER POINTS FOR DIRECTED EVOLUTION
|
GRANTED
|
11/818237
|
06/12/2007
|
20397
|
8224580
|
07/17/2012
|
CODEXIS MAYFLOWER PATENTS
|
|||||||
US
|
OPTIMIZATION OF CROSSOVER POINTS FOR DIRECTED EVOLUTION
|
GRANTED
|
10/386903
|
03/10/2003
|
198988
|
7620500
|
11/17/2009
|
EP
|
OPTIMIZATION OF CROSSOVER POINTS FOR DIRECTED EVOLUTION
|
PUBLISHED
|
3711540.9
|
03/10/2003
|
1488335
|
|
|
US
|
INTEGRATED SYSTEMS AND METHODS FOR DIVERSITY GENERATION AND SCREENING
|
GRANTED
|
11/677505
|
02/21/2007
|
15116
|
8014961
|
09/06/2011
|
US
|
INTEGRATED SYSTEMS AND METHODS FOR DIVERSITY GENERATION AND SCREENING
|
GRANTED
|
10/154936
|
05/23/2002
|
54383
|
7462469
|
12/09/2008
|
US
|
METHODS OF POPULATING DATA STRUCTURES FOR USE IN EVOLUTIONARY SIMULATIONS
|
GRANTED
|
12/557746
|
09/11/2009
|
241640
|
8170806
|
05/01/2012
|
US
|
METHODS OF POPULATING DATA STRUCTURES FOR USE IN EVOLUTIONARY SIMULATIONS
|
GRANTED
|
11/973805
|
10/09/2007
|
40045
|
7873499
|
01/18/2011
|
US
|
METHODS OF POPULATING DATA STRUCTURES FOR USE IN EVOLUTIONARY SIMULATIONS
|
GRANTED
|
11/210239
|
08/22/2005
|
47611
|
7430477
|
09/30/2008
|
US
|
METHODS OF POPULATING DATA STRUCTURES FOR USE IN EVOLUTIONARY SIMULATIONS
|
GRANTED
|
09/495668
|
02/01/2000
|
32010
|
6961664
|
11/01/2005
|
CA
|
METHODS OF POPULATING DATA STRUCTURES FOR USE IN EVOLUTIONARY SIMULATIONS
|
GRANTED
|
2337949
|
01/18/2000
|
2337949
|
2337949
|
03/15/2011
|
US
|
METHODS OF POPULATING DATA STRUCTURES FOR USE IN EVOLUTIONARY SIMULATIONS
|
GRANTED
|
13/434261
|
03/29/2012
|
20120252684A1
|
8589085
|
11/19/2013
|
US
|
METHOD AND SYSTEM USING SYSTEMATICALLY VARIED DATA LIBRARIES
|
GRANTED
|
10/225564
|
08/20/2002
|
|
7873477
|
01/18/2011
|
CODEXIS MAYFLOWER PATENTS
|
|||||||
US
|
METHOD AND APPARATUS FOR PREFERREED CODON DETERMINING SIMULATIONS
|
GRANTED
|
10/232770
|
08/30/2002
|
|
7702464
|
04/20/2010
|
US
|
METHOD AND APPARATUS FOR PREFERREED CODON DETERMINING SIMULATIONS
|
GRANTED
|
13/229228
|
09/09/2011
|
|
8457903
|
06/04/2013
|
EP
|
METHODS, SYSTEMS AND SOFTWARE FOR IDENTIFYING FUNCTIONAL BIOMOLECULES
|
GRANTED
|
10181057.0
|
09/28/2010
|
2390803
|
2390803
|
11/20/2013
|
US
|
METHODS, SYSTEMS AND SOFTWARE FOR IDENTIFYING FUNCTIONAL BIOMOLECULES
|
PUBLISHED
|
12/979,637
|
12/28/2010
|
20110161265
|
|
|
JP
|
METHODS, SYSTEMS AND SOFTWARE FOR IDENTIFYING FUNCTIONAL BIOMOLECULES
|
GRANTED
|
2003-573522
|
03/03/2003
|
|
5319865
|
07/19/2013
|
US
|
METHODS, SYSTEMS AND SOFTWARE FOR IDENTIFYING FUNCTIONAL BIOMOLECULES
|
GRANTED
|
11/981577
|
10/30/2007
|
133143
|
7751986
|
07/06/2010
|
US
|
METHODS, SYSTEMS AND SOFTWARE FOR IDENTIFYING FUNCTIONAL BIOMOLECULES
|
GRANTED
|
11/706034
|
02/12/2007
|
239364
|
7747393
|
06/29/2010
|
US
|
METHODS, SYSTEMS AND SOFTWARE FOR IDENTIFYING FUNCTIONAL BIOMOLECULES
|
GRANTED
|
11/429628
|
05/05/2006
|
205003
|
8849575
|
09/30/2014
|
US
|
METHODS, SYSTEMS AND SOFTWARE FOR IDENTIFYING FUNCTIONAL BIOMOLECULES
|
GRANTED
|
10/629351
|
07/29/2003
|
161796
|
7747391
|
06/29/2010
|
US
|
METHODS, SYSTEMS AND SOFTWARE FOR IDENTIFYING FUNCTIONAL BIOMOLECULES
|
GRANTED
|
10/379378
|
03/03/2003
|
72245
|
7783428
|
08/24/2010
|
EP
|
METHODS, SYSTEMS AND SOFTWARE FOR IDENTIFYING FUNCTIONAL BIOMOLECULES
|
GRANTED
|
5779687.2
|
06/21/2005
|
1761879
|
1761879
|
08/14/2013
|
CODEXIS MAYFLOWER PATENTS
|
|||||||
EP
|
METHODS, SYSTEMS AND SOFTWARE FOR IDENTIFYING FUNCTIONAL BIOMOLECULES
|
GRANTED
|
3743748.0
|
03/03/2003
|
1493027
|
1493027
|
10/15/2014
|
EP
|
METHODS, SYSTEMS AND SOFTWARE FOR IDENTIFYING FUNCTIONAL BIOMOLECULES
|
GRANTED
|
10181000.0
|
09/28/2010
|
2278509
|
2278509
|
11/19/2014
|
BE
|
METHODS, SYSTEMS AND SOFTWARE FOR IDENTIFYING FUNCTIONAL BIOMOLECULES
|
GRANTED
|
5779687.2
|
06/21/2005
|
1761879
|
1761879
|
08/14/2013
|
FR
|
METHODS, SYSTEMS AND SOFTWARE FOR IDENTIFYING FUNCTIONAL BIOMOLECULES
|
GRANTED
|
5779687.2
|
06/21/2005
|
1761879
|
1761879
|
08/14/2013
|
GB
|
METHODS, SYSTEMS AND SOFTWARE FOR IDENTIFYING FUNCTIONAL BIOMOLECULES
|
GRANTED
|
5779687.2
|
06/21/2005
|
1761879
|
1761879
|
08/14/2013
|
DE
|
METHODS, SYSTEMS AND SOFTWARE FOR IDENTIFYING FUNCTIONAL BIOMOLECULES
|
GRANTED
|
5779687.2
|
06/21/2005
|
1761879
|
1761879
|
08/14/2013
|
DK
|
METHODS, SYSTEMS AND SOFTWARE FOR IDENTIFYING FUNCTIONAL BIOMOLECULES
|
GRANTED
|
5779687.2
|
06/21/2005
|
1761879
|
1761879
|
08/14/2013
|
BE
|
METHODS, SYSTEMS AND SOFTWARE FOR IDENTIFYING FUNCTIONAL BIOMOLECULES
|
GRANTED
|
10181057.0
|
09/28/2010
|
2390803
|
2390803
|
11/20/2013
|
GB
|
METHODS, SYSTEMS AND SOFTWARE FOR IDENTIFYING FUNCTIONAL BIOMOLECULES
|
GRANTED
|
10181057.0
|
09/28/2010
|
2390803
|
2390803
|
11/20/2013
|
DE
|
METHODS, SYSTEMS AND SOFTWARE FOR IDENTIFYING FUNCTIONAL BIOMOLECULES
|
GRANTED
|
10181057.0
|
09/28/2010
|
2390803
|
2390803
|
11/20/2013
|
NL
|
METHODS, SYSTEMS AND SOFTWARE FOR IDENTIFYING FUNCTIONAL BIOMOLECULES
|
GRANTED
|
10181057.0
|
09/28/2010
|
2390803
|
2390803
|
11/20/2013
|
CODEXIS MAYFLOWER PATENTS
|
|||||||
US
|
METHODS, SYSTEMS AND SOFTWARE FOR IDENTIFYING FUNCTIONAL BIOMOLECULES
|
PUBLISHED
|
14/256692
|
04/18/2014
|
2014/0249035
|
|
|
FR
|
METHODS, SYSTEMS AND SOFTWARE FOR IDENTIFYING FUNCTIONAL BIOMOLECULES
|
GRANTED
|
10181057.0
|
09/28/2010
|
2390803
|
2390803
|
11/20/2013
|
CH
|
METHODS, SYSTEMS AND SOFTWARE FOR IDENTIFYING FUNCTIONAL BIOMOLECULES
|
GRANTED
|
10181057.0
|
09/28/2010
|
2390803
|
2390803
|
11/20/2013
|
DK
|
METHODS, SYSTEMS AND SOFTWARE FOR IDENTIFYING FUNCTIONAL BIOMOLECULES
|
GRANTED
|
10181057.0
|
09/28/2010
|
2390803
|
2390803
|
11/20/2013
|
CH
|
METHODS, SYSTEMS AND SOFTWARE FOR IDENTIFYING FUNCTIONAL BIOMOLECULES
|
GRANTED
|
5779687.2
|
06/21/2005
|
1761879
|
1761879
|
08/14/2013
|
NL
|
METHODS, SYSTEMS AND SOFTWARE FOR IDENTIFYING FUNCTIONAL BIOMOLECULES
|
GRANTED
|
5779687.2
|
06/21/2005
|
1761879
|
1761879
|
08/14/2013
|
SE
|
METHODS, SYSTEMS AND SOFTWARE FOR IDENTIFYING FUNCTIONAL BIOMOLECULES
|
GRANTED
|
3743748.0
|
03/03/2003
|
1493027
|
1493027
|
10/15/2014
|
DK
|
METHODS, SYSTEMS AND SOFTWARE FOR IDENTIFYING FUNCTIONAL BIOMOLECULES
|
GRANTED
|
3743748.0
|
03/03/2003
|
1493027
|
1493027
|
10/15/2014
|
FR
|
METHODS, SYSTEMS AND SOFTWARE FOR IDENTIFYING FUNCTIONAL BIOMOLECULES
|
GRANTED
|
3743748.0
|
03/03/2003
|
1493027
|
1493027
|
10/15/2014
|
IE
|
METHODS, SYSTEMS AND SOFTWARE FOR IDENTIFYING FUNCTIONAL BIOMOLECULES
|
GRANTED
|
3743748.0
|
03/03/2003
|
1493027
|
1493027
|
10/15/2014
|
NL
|
METHODS, SYSTEMS AND SOFTWARE FOR IDENTIFYING FUNCTIONAL BIOMOLECULES
|
GRANTED
|
3743748.0
|
03/03/2003
|
1493027
|
1493027
|
10/15/2014
|
CODEXIS MAYFLOWER PATENTS
|
|||||||
BE
|
METHODS, SYSTEMS AND SOFTWARE FOR IDENTIFYING FUNCTIONAL BIOMOLECULES
|
GRANTED
|
3743748.0
|
03/03/2003
|
1493027
|
1493027
|
10/15/2014
|
DE
|
METHODS, SYSTEMS AND SOFTWARE FOR IDENTIFYING FUNCTIONAL BIOMOLECULES
|
GRANTED
|
3743748.0
|
03/03/2003
|
1493027
|
60346889.6
|
10/15/2014
|
HU
|
METHODS, SYSTEMS AND SOFTWARE FOR IDENTIFYING FUNCTIONAL BIOMOLECULES
|
GRANTED
|
3743748.0
|
03/03/2003
|
1493027
|
1493027
|
10/15/2014
|
IT
|
METHODS, SYSTEMS AND SOFTWARE FOR IDENTIFYING FUNCTIONAL BIOMOLECULES
|
GRANTED
|
3743748.0
|
03/03/2003
|
1493027
|
1493027
|
10/15/2014
|
CH
|
METHODS, SYSTEMS AND SOFTWARE FOR IDENTIFYING FUNCTIONAL BIOMOLECULES
|
GRANTED
|
3743748.0
|
03/03/2003
|
1493027
|
1493027
|
10/15/2014
|
GB
|
METHODS, SYSTEMS AND SOFTWARE FOR IDENTIFYING FUNCTIONAL BIOMOLECULES
|
GRANTED
|
3743748.0
|
03/03/2003
|
1493027
|
1493027
|
10/15/2014
|
DK
|
METHODS, SYSTEMS AND SOFTWARE FOR IDENTIFYING FUNCTIONAL BIOMOLECULES
|
GRANTED
|
10181000.0
|
09/28/2010
|
2278509
|
2278509
|
11/19/2014
|
HU
|
METHODS, SYSTEMS AND SOFTWARE FOR IDENTIFYING FUNCTIONAL BIOMOLECULES
|
GRANTED
|
10181000.0
|
09/28/2010
|
2278509
|
2278509
|
11/19/2014
|
IE
|
METHODS, SYSTEMS AND SOFTWARE FOR IDENTIFYING FUNCTIONAL BIOMOLECULES
|
GRANTED
|
10181000.0
|
09/28/2010
|
2278509
|
2278509
|
11/19/2014
|
IT
|
METHODS, SYSTEMS AND SOFTWARE FOR IDENTIFYING FUNCTIONAL BIOMOLECULES
|
GRANTED
|
10181000.0
|
09/28/2010
|
2278509
|
2278509
|
11/19/2014
|
CH
|
METHODS, SYSTEMS AND SOFTWARE FOR IDENTIFYING FUNCTIONAL BIOMOLECULES
|
GRANTED
|
10181000.0
|
09/28/2010
|
2278509
|
2278509
|
11/19/2014
|
CODEXIS MAYFLOWER PATENTS
|
|||||||
GB
|
METHODS, SYSTEMS AND SOFTWARE FOR IDENTIFYING FUNCTIONAL BIOMOLECULES
|
GRANTED
|
10181000.0
|
09/28/2010
|
2278509
|
2278509
|
11/19/2014
|
US
|
METHODS, SYSTEMS AND SOFTWARE FOR IDENTIFYING FUNCTIONAL BIOMOLECULES
|
PUBLISHED
|
14/536242
|
11/07/2014
|
20150065357
|
|
|
DE
|
METHODS, SYSTEMS AND SOFTWARE FOR IDENTIFYING FUNCTIONAL BIOMOLECULES
|
GRANTED
|
10181000.0
|
09/28/2010
|
2278509
|
60347028.9
|
11/19/2014
|
BE
|
METHODS, SYSTEMS AND SOFTWARE FOR IDENTIFYING FUNCTIONAL BIOMOLECULES
|
GRANTED
|
10181000.0
|
09/28/2010
|
2278509
|
2278509
|
11/19/2014
|
FR
|
METHODS, SYSTEMS AND SOFTWARE FOR IDENTIFYING FUNCTIONAL BIOMOLECULES
|
GRANTED
|
10181000.0
|
09/28/2010
|
2278509
|
2278509
|
11/19/2014
|
NL
|
METHODS, SYSTEMS AND SOFTWARE FOR IDENTIFYING FUNCTIONAL BIOMOLECULES
|
GRANTED
|
10181000.0
|
09/28/2010
|
2278509
|
2278509
|
11/19/2014
|
SE
|
METHODS, SYSTEMS AND SOFTWARE FOR IDENTIFYING FUNCTIONAL BIOMOLECULES
|
GRANTED
|
10181000.0
|
09/28/2010
|
2278509
|
2278509
|
11/19/2014
|
US
|
METHODS, SYSTEMS AND SOFTWARE FOR IDENTIFYING FUNCTIONAL BIOMOLECULES
|
GRANTED
|
11/981578
|
10/30/2007
|
132416
|
8762066
|
06/24/2014
|
EP
|
METHODS, SYSTEMS AND SOFTWARE FOR IDENTIFYING FUNCTIONAL BIOMOLECULES
|
ALLOWED
|
10181159.4
|
09/28/2010
|
2315145
|
|
|
IN-LICENSED PATENTS
|
|||||||
Country
|
Application Title
|
Application Status
|
Application No.
|
Filing Date
|
Publication No.
|
Pat. No.
|
Issue Date
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
|
|
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
|
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
|
|
[***]
|
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
||
[***]
|
[***]
|
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
|
[***]
|
[***]
|
|
[***]
|
[***]
|
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
|
[***]
|
[***]
|
|
[***]
|
[***]
|
|
[***]
|
[***]
|
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
|
[***]
|
[***]
|
|
[***]
|
[***]
|
|
[***]
|
[***]
|
|
[***]
|
[***]
|
|
[***]
|
[***]
|
|
[***]
|
[***]
|
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
|
[***]
|
[***]
|
[***]
|
[***]
|
||
[***]
|
[***]
|
|
[***]
|
[***]
|
|
[***]
|
[***]
|
|
[***]
|
[***]
|
|
[***]
|
[***]
|
|
[***]
|
[***]
|
|
[***]
|
[***]
|
|
[***]
|
[***]
|
|
[***]
|
[***]
|
|
CODEXIS CONFIDENTIAL INFORMATION
|
1.
|
EXECUTIVE SUMMARY
|
Wave 1:
|
Transfer of [***] to MERCK.
|
a.
|
Set-up of the Designated Lab; including access to the Codexis Software.
|
b.
|
[***] in Codexis labs in Redwood City, CA (“RWC”) [***]
|
c.
|
[***] in the Designated Lab [***]
|
d.
|
Training at Redwood City, CA in [***].
|
•
|
[***]
|
1.
|
[***]
|
2.
|
[***]
|
3.
|
[***]
|
4.
|
[***]
|
5.
|
[***]
|
1)
|
[***]
|
2)
|
[***]
|
3)
|
[***]
|
4)
|
[***]
|
•
|
[***]
|
1.
|
[***]
|
2.
|
[***]
|
•
|
[***]
|
3.
|
[***]
|
•
|
[***]
|
•
|
[***]
|
•
|
[***]
|
•
|
[***]
|
•
|
[***]
|
•
|
[***]
|
•
|
[***]
|
•
|
[***]
|
•
|
[***]
|
•
|
[***]
|
•
|
[***]
|
1)
|
[***]:
|
A)
|
[***]
|
Platform
|
Short
Name
|
# of 96-well
Plates
per Panel
|
# of Enzymes
per Kit
|
Format
|
Quantity
Provided
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
•
|
[***]
|
•
|
[***]
|
•
|
[***]
|
2)
|
[***]
|
Platform
|
Short Name
|
Format
|
Number of Enzymes
|
Quantity
Provided
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
3)
|
[***]
|
Principal Equipment
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
[***]
|
•
|
[***]
|
•
|
[***]
|
•
|
[***]
|
•
|
[***]
|
•
|
[***]
|
•
|
[***]
|
•
|
[***]
|
Codexis, Inc.
(“
Codexis
”)
|
_______________________
(“
Merck
”)
|
200 Penobscot Dr.
|
__________________________________
|
Redwood City, CA 94063
|
__________________________________
|
|
|
I.
|
[***]
|
1.
|
I have reviewed this Quarterly Report on Form 10-Q of Codexis, Inc.;
|
2.
|
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
|
3.
|
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
|
4.
|
The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
|
(a)
|
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
|
(b)
|
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
|
(c)
|
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
|
(d)
|
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
|
5.
|
The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
|
(a)
|
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
|
(b)
|
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
|
/s/ John Nicols
|
John Nicols
|
President and Chief Executive Officer
(principal executive officer)
|
1.
|
I have reviewed this Quarterly Report on Form 10-Q of Codexis, Inc.;
|
2.
|
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
|
3.
|
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
|
4.
|
The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
|
(a)
|
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
|
(b)
|
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
|
(c)
|
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
|
(d)
|
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
|
5.
|
The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
|
(a)
|
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
|
(b)
|
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
|
/s/ Gordon Sangster
|
Gordon Sangster
Senior Vice President and Chief Financial Officer
|
(principal financial and accounting officer)
|
•
|
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
|
•
|
The information in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
|
/s/ John Nicols
|
John Nicols
|
President and Chief Executive Officer
(principal executive officer)
|
|
/s/ Gordon Sangster
|
Gordon Sangster
Senior Vice President and Chief Financial Officer |
(principal financial and accounting officer)
|